<?xml version="1.0" encoding="UTF-8"?><OAI-PMH
	xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2019-03-02T19:27:45Z</responseDate><request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:2075524" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request><GetRecord><record><header><identifier>oai:pubmedcentral.nih.gov:2075524</identifier><datestamp>2007-11-13</datestamp><setSpec>bmcgeno</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns="https://dtd.nlm.nih.gov/ns/archiving/2.3/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://dtd.nlm.nih.gov/ns/archiving/2.3/ https://dtd.nlm.nih.gov/archiving/2.3/xsd/archivearticle.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">BMC Genomics</journal-id>
      <journal-title>BMC Genomics</journal-title>
      <issn pub-type="epub">1471-2164</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC2075524</article-id>
      <article-id pub-id-type="pmcid">PMC2075524</article-id>
      <article-id pub-id-type="pmc-uid">2075524</article-id>
      <article-id pub-id-type="pmid">17845732</article-id>
      <article-id pub-id-type="publisher-id">1471-2164-8-318</article-id>
      <article-id pub-id-type="pmid">17845732</article-id>
      <article-id pub-id-type="doi">10.1186/1471-2164-8-318</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Research Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Alternative splicing of TGF-betas and their high-affinity receptors TÎ²RI, TÎ²RII and TÎ²RIII (betaglycan) reveal new variants in human prostatic cells</article-title>
      </title-group>
      <contrib-group>
        <contrib id="A1" corresp="yes" contrib-type="author">
          <name>
            <surname>Konrad</surname>
            <given-names>Lutz</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>Konrad@med.uni-marburg.de</email>
        </contrib>
        <contrib id="A2" contrib-type="author">
          <name>
            <surname>Scheiber</surname>
            <given-names>Jonas A</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>JonasScheiber@web.de</email>
        </contrib>
        <contrib id="A3" contrib-type="author">
          <name>
            <surname>VÃ¶lck-Badouin</surname>
            <given-names>Elke</given-names>
          </name>
          <xref ref-type="aff" rid="I2">2</xref>
          <email>elke.voelk-badouin@staff.uni-marburg.de</email>
        </contrib>
        <contrib id="A4" contrib-type="author">
          <name>
            <surname>Keilani</surname>
            <given-names>Marcel M</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>Keilani.m@gmx.de</email>
        </contrib>
        <contrib id="A5" contrib-type="author">
          <name>
            <surname>Laible</surname>
            <given-names>Leslie</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>Leslie.Laible@gmx.de</email>
        </contrib>
        <contrib id="A6" contrib-type="author">
          <name>
            <surname>Brandt</surname>
            <given-names>Heidrun</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>brandth@med.uni-marburg.de</email>
        </contrib>
        <contrib id="A7" contrib-type="author">
          <name>
            <surname>Schmidt</surname>
            <given-names>Ansgar</given-names>
          </name>
          <xref ref-type="aff" rid="I3">3</xref>
          <email>ansschmi@med.uni-marburg.de</email>
        </contrib>
        <contrib id="A8" contrib-type="author">
          <name>
            <surname>AumÃ¼ller</surname>
            <given-names>Gerhard</given-names>
          </name>
          <xref ref-type="aff" rid="I2">2</xref>
          <email>aumuelle@post.med.uni-marburg.de</email>
        </contrib>
        <contrib id="A9" contrib-type="author">
          <name>
            <surname>Hofmann</surname>
            <given-names>Rainer</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>Rainer.Hofmann@med.uni-marburg.de</email>
        </contrib>
      </contrib-group>
      <aff id="I1"><label>1</label>Department of Urology, Medical Faculty, 35033 Marburg, Germany</aff>
      <aff id="I2"><label>2</label>Department of Anatomy and Cell Biology, Medical Faculty, 35033 Marburg, Germany</aff>
      <aff id="I3"><label>3</label>Department of Pathology, Medical Faculty, 35033 Marburg, Germany</aff>
      <pub-date pub-type="collection">
        <year>2007</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>11</day>
        <month>9</month>
        <year>2007</year>
      </pub-date>
      <volume>8</volume>
      <fpage>318</fpage>
      <lpage>318</lpage>
      <ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2164/8/318"/>
      <history>
        <date date-type="received">
          <day>24</day>
          <month>5</month>
          <year>2007</year>
        </date>
        <date date-type="accepted">
          <day>11</day>
          <month>9</month>
          <year>2007</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright Â© 2007 Konrad et al; licensee BioMed Central Ltd.</copyright-statement>
        <copyright-year>2007</copyright-year>
        <copyright-holder>Konrad et al; licensee BioMed Central Ltd.</copyright-holder>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0">
          <p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p>
          <!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author>
               Konrad
               Lutz
               
               Konrad@med.uni-marburg.de
            </dc:author><dc:title>
            Alternative splicing of TGF-betas and their high-affinity receptors T&#x003b2;RI, T&#x003b2;RII and T&#x003b2;RIII (betaglycan) reveal new variants in human prostatic cells
         </dc:title><dc:date>2007</dc:date><dcterms:bibliographicCitation>BMC Genomics 8(1): 318-. (2007)</dcterms:bibliographicCitation><dc:identifier type="sici">1471-2164(2007)8:1&#x0003c;318&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1471-2164</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>-->
        </license>
      </permissions>
      <abstract>
        <sec>
          <title>Background</title>
          <p>The transforming growth factors (TGF)-Î², TGF-Î²1, TGF-Î²2 and TGF-Î²3, and their receptors [TÎ²RI, TÎ²RII, TÎ²RIII (betaglycan)] elicit pleiotropic functions in the prostate. Although expression of the ligands and receptors have been investigated, the splice variants have never been analyzed. We therefore have analyzed all ligands, the receptors and the splice variants TÎ²RIB, TÎ²RIIB and TGF-Î²2B in human prostatic cells.</p>
        </sec>
        <sec>
          <title>Results</title>
          <p>Interestingly, a novel human receptor transcript TÎ²RIIC was identified, encoding additional 36 amino acids in the extracellular domain, that is expressed in the prostatic cancer cells PC-3, stromal hPCPs, and other human tissues. Furthermore, the receptor variant TÎ²RIB with four additional amino acids was identified also in human. Expression of the variant TÎ²RIIB was found in all prostate cell lines studied with a preferential localization in epithelial cells in some human prostatic glands. Similarly, we observed localization of TÎ²RIIC and TGF-Î²2B mainly in the epithelial cells with a preferential localization of TGF-Î²2B in the apical cell compartment. Whereas in the androgen-independent hPCPs and PC-3 cells all TGF-Î² ligands and receptors are expressed, the androgen-dependent LNCaP cells failed to express all ligands. Additionally, stimulation of PC-3 cells with TGF-Î²2 resulted in a significant and strong increase in secretion of plasminogen activator inhibitor-1 (PAI-1) with a major participation of TÎ²RII.</p>
        </sec>
        <sec>
          <title>Conclusion</title>
          <p>In general, expression of the splice variants was more heterogeneous in contrast to the well-known isoforms. The identification of the splice variants TÎ²RIB and the novel isoform TÎ²RIIC in man clearly contributes to the growing complexity of the TGF-Î² family.</p>
        </sec>
      </abstract>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>Background</title>
      <p>Transforming growth factor (TGF)-Î² is a secreted cytokine implicated in a wide variety of biological processes such as apoptosis, motility, tumorigenesis, proliferation, differentiation, and gene expression [<xref ref-type="bibr" rid="B1">1</xref>]. In mammals three TGF-betas, TGF-Î²1, TGF-Î²2 and TGF-Î²3, have been cloned, and although they show very often overlapping functions in vitro, the isoform-specific knockout mice revealed non-redundant and non-overlapping phenotypes. Approximately 50% of the TGF-Î²1 knockout mice died during embryogenesis from yolk sac defects; the survivors developed inflammatory disorders and died typically within one month [<xref ref-type="bibr" rid="B2">2</xref>-<xref ref-type="bibr" rid="B4">4</xref>]. TGF-Î²2 knockout mice were perinatally lethal and developed defects in different organs such as heart, kidney, testis, as well as various craniofacial defects and axial and appendicular skeletal defects [<xref ref-type="bibr" rid="B5">5</xref>]. Moreover, TGF-Î²3 knockout mice were perinatally lethal due to a delayed lung development and defective palatogenesis [<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B7">7</xref>].</p>
      <p>Secretion and inactivation of the TGF-betas is regulated by the latency-associated peptides (LAPs) which are generated from the respective N-terminal TGF-Î² proteins by cleavage [<xref ref-type="bibr" rid="B8">8</xref>]. Additionally, latent TGF-Î² binding proteins (LTBP1-4) are covalently attached to the LAPs and mediate storage in the extracellular matrix (ECM). After activation by proteolytic enzymes or acidic environment the TGF-betas bind with high affinity to the serine/threonine kinase receptor TÎ²RII which in turns phosphorylates TÎ²RI. Activation of the receptor complex propagates the signal downstream to the Smad proteins, who regulate many TGF-Î²-induced transcriptional responses [<xref ref-type="bibr" rid="B9">9</xref>]. Alternatively, TGF-Î²2 can bind to the accessory receptor TÎ²RIII, who facilitates binding of TGF-Î²2 to TÎ²RII. However, signal transduction is initiated again by TÎ²RI. Recently, it was shown that TGF-Î²2 might also bind to an alternative splice product of the TÎ²RII gene, mainly expressed in osteoblasts and mesenchymal cells. The receptor isoform TÎ²RIIB binds TGF-Î²2 also in the absence of TÎ²RIII and then activates TÎ²RI starting the signal transduction [<xref ref-type="bibr" rid="B10">10</xref>]. However, recently it was shown in human chondrocytes that TÎ²RIIB exerted a higher affinity for TGF-Î²1 than for TGF-Î²2 [<xref ref-type="bibr" rid="B11">11</xref>]. In addition to alternative splicing of TÎ²RII, TGF-Î²2 and TÎ²RI also were demonstrated to be alternatively spliced in human prostatic PC-3 cells [<xref ref-type="bibr" rid="B12">12</xref>] and embryonic stem cells from mouse [<xref ref-type="bibr" rid="B13">13</xref>], respectively.</p>
      <p>TGF-betas are believed to be involved in several aspects of carcinogenesis. At the beginning of tumor formation the TGF-betas might inhibit proliferation of cancer cells, but with ongoing dedifferentiation, the TGF-betas and the receptors seem to enhance motility and metastasis of the tumor cells [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B14">14</xref>]. In more advanced and especially metastasised stages higher serum levels of TGF-Î²1 were found [<xref ref-type="bibr" rid="B15">15</xref>] and reduced expression of TÎ²RII and TÎ²RI in the tumor tissue was associated with poor prognosis [<xref ref-type="bibr" rid="B16">16</xref>].</p>
      <p>Recently, analyses of alternative splicing indicated that approximately 40â60% of human genes express splice variants, suggesting that alternative splicing contributes to the growing complexity of the human genome [<xref ref-type="bibr" rid="B17">17</xref>]. In many transcripts, addition or deletion of complete exons or introduction of an early stop codon may result in a truncated or unstable mRNA [<xref ref-type="bibr" rid="B18">18</xref>]. Alternative splicing has been shown to be involved in ligand binding to growth factor receptors like TÎ²RIIB [<xref ref-type="bibr" rid="B10">10</xref>], cell adhesion or various human diseases [<xref ref-type="bibr" rid="B19">19</xref>]. Additionally, alternative splicing occurs sometimes during developmental processes and may be restricted to distinct tissues [<xref ref-type="bibr" rid="B18">18</xref>]. Interestingly, it was reported that more alternative splicing was found in organs such as testis, pancreas, placenta, and liver [<xref ref-type="bibr" rid="B20">20</xref>]. Up to date many groups have presented genomic analyses of alternative splicing by use of expressed sequence tags (EST, [e.g. [<xref ref-type="bibr" rid="B21">21</xref>-<xref ref-type="bibr" rid="B23">23</xref>]] or microarrays [<xref ref-type="bibr" rid="B20">20</xref>]. Most of these results are now available in databases [<xref ref-type="bibr" rid="B17">17</xref>].</p>
      <p>In this study, we have analyzed the mRNA expression of the TGF-betas and the receptors TÎ²RI-III mainly in human prostatic cells available to us and identified the splice variants TGF-Î²2B, TÎ²RIB, TÎ²RIIB and the new variant TÎ²RIIC. Of note, the alternatively spliced exons were found in the N-terminal part of the proteins and extracellular domains of the receptors. The splice variant TGF-Î²2B could be identified in more species than the other isoforms and showed less sequence variation among the various species. Furthermore, this is the first report showing localization of the splice variants TÎ²RIIB, TÎ²RIIC and TGF-Î²2B in human prostate tissue.</p>
    </sec>
    <sec>
      <title>Results</title>
      <sec>
        <title>Literature and database search for alternative splicing</title>
        <p>The search in the literature (PubMed) and sequence databases for TGF-betas and their high-affinity receptors displayed deleted or additional exons. Alternative splicing of the TGF-beta ligands was described for TGF-Î²1 in pig [<xref ref-type="bibr" rid="B24">24</xref>] and for TGF-Î²2 in human and rat [<xref ref-type="bibr" rid="B12">12</xref>,<xref ref-type="bibr" rid="B25">25</xref>]. Alternative splicing of the high-affinity receptors was demonstrated for TÎ²RI in mouse, rat and boar [<xref ref-type="bibr" rid="B13">13</xref>,<xref ref-type="bibr" rid="B26">26</xref>,<xref ref-type="bibr" rid="B27">27</xref>], and for TÎ²RII in mouse and human [<xref ref-type="bibr" rid="B28">28</xref>-<xref ref-type="bibr" rid="B30">30</xref>].</p>
        <p>In the database ASDB [<xref ref-type="bibr" rid="B21">21</xref>], dealing with alternative splicing, TGF-Î²2 and TGF-Î²3 were mentioned to contain splice variants, and in the database ASAP [<xref ref-type="bibr" rid="B31">31</xref>] three isoforms for TGF-Î²1 were described. The database EASED [<xref ref-type="bibr" rid="B32">32</xref>] showed many but not all of the aberrant ESTs which were found in this study.</p>
      </sec>
      <sec>
        <title>Alternative splicing and mRNA expression of TÎ²RI</title>
        <p>Alignment of the human ESTs with the genomic sequence of the TÎ²RI revealed several irregular ESTs but none of them with additional exons. We also identified a pseudogene of the TÎ²RI gene on chromosome 19 reaching from exon 2 to exon 4 and a short stretch of 62 base pairs (bp) from the 3'-UTR (Fig. <xref ref-type="fig" rid="F1">1A</xref>). The pseudogene showed 87 sequence aberrations in 550 bp (16%) compared to the TÎ²RI cDNA.</p>
        <fig position="float" id="F1">
          <label>Figure 1</label>
          <caption>
            <p>(<bold>A</bold>) Comparison of the exon structure of the human TÎ²RI mRNA with the pseudogene on chromosome 19. A detailed alignment of the pseudogene with exons 2 to 4 and the 3'-UTR is available from the authors upon request. Lines depict the 5'-UTR and 3'-UTR. The repetitive elements AluSX, AluSB and L1Pa13 are encircled. (<bold>B</bold>) Expression pattern of the TÎ²RI gene in human prostatic cells. Expression of both transcript variants (upper panel, 5-TB1RL/3-TB1RL) and expression of the splice variant TÎ²RIB (lower panel; 5-TB1RL/3-HTB1RL) is demonstrated. (<bold>C</bold>) Scheme of the TÎ²RI protein (EC, extracellular domain; TM, transmembrane domain; kinase, Ser/Thr kinase domain) with the nucleotide and amino acid sequence of exon 2 and exon 3 (capital letters) and the alternatively spliced exon 3B (lower case letters). Additionally, the partial sequence without the alternatively spliced exon is given below. The sequence of TÎ²RI was not available for canis familiaris. The splice site junctions are indicated by italic letters. Bold letters mark the amino acid and nucleotide exchanges with respect to the human sequence. The accession numbers are given below (hs, homo sapiens; mm, mus musculus; rn, rattus norvegicus; ss, sus scrofa; cf, canis familiaris). Arrows indicate the exon boundaries. Ctrl, control.</p>
          </caption>
          <graphic xlink:href="1471-2164-8-318-1"/>
        </fig>
        <p>A 12 bp extension of the third exon of the TÎ²RI was first found in mouse and rat [<xref ref-type="bibr" rid="B13">13</xref>,<xref ref-type="bibr" rid="B26">26</xref>] and recently in boars [<xref ref-type="bibr" rid="B27">27</xref>], but not in human. Therefore, we cloned both variants of TÎ²RI, with and without the 12 bp extension (Acc. Nos. <ext-link ext-link-type="gen" xlink:href="AJ619019">AJ619019</ext-link> and <ext-link ext-link-type="gen" xlink:href="AJ619020">AJ619020</ext-link>, respectively) from the human stromal cells hPCPs [<xref ref-type="bibr" rid="B33">33</xref>] (Figs. <xref ref-type="fig" rid="F1">1A,B</xref>). mRNA expression of TÎ²RI and TÎ²RIB was found in the stromal hPCPs cells and epithelial LNCaP cells, whereas PC-3 cells only expressed TÎ²RI and not TÎ²RIB (Fig. <xref ref-type="fig" rid="F1">1B</xref>). Because the splice variant TÎ²RIB was only weakly expressed, we obtained improved PCR results by using a primer containing the 12 bp extension (Fig. <xref ref-type="fig" rid="F1">1B</xref>, Table <xref ref-type="table" rid="T1">1</xref>). The additional exon 3B codes for 4 amino acids in the extracellular domain of the receptor and is also found in dogs and pigs (Fig. <xref ref-type="fig" rid="F1">1C</xref>). Up to date, the sequence of TÎ²RI is not available for Canis familiaris (Fig. <xref ref-type="fig" rid="F1">1C</xref>). According to the exon classification [<xref ref-type="bibr" rid="B34">34</xref>] exon 3B with the 12 bp extension belongs to the exon-type with internal acceptor sites.</p>
        <table-wrap position="float" id="T1">
          <label>Table 1</label>
          <caption>
            <p>Primer pairs used for characterization</p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <td align="left">
                  <bold>Gene (Acc No)<sup>a</sup></bold>
                </td>
                <td align="left">
                  <bold>Position</bold>
                </td>
                <td align="left">
                  <bold>Designation</bold>
                </td>
                <td align="left">
                  <bold>Size</bold>
                </td>
                <td align="left">
                  <bold>Sequence</bold>
                </td>
                <td align="left">
                  <bold>AT<sup>b</sup></bold>
                </td>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td align="left">TÎ²RI, human,</td>
                <td align="left">256â275<sup>c</sup></td>
                <td align="left">5-TB1RL</td>
                <td align="left">288 bp</td>
                <td align="left">GACCACAGACAAAGTTATAC</td>
                <td align="left">60Â°C</td>
              </tr>
              <tr>
                <td align="left">(<ext-link ext-link-type="gen" xlink:href="NM_004612">NM_004612</ext-link>)</td>
                <td align="left">524â543</td>
                <td align="left">3-TB1RL</td>
                <td align="left">300 bp</td>
                <td align="left">TGGTGAATGACAGTGCGGTT</td>
                <td/>
              </tr>
              <tr>
                <td align="left">(<ext-link ext-link-type="gen" xlink:href="AJ619019">AJ619019</ext-link>)</td>
                <td align="left">159â178</td>
                <td align="left">3-HTB1RL</td>
                <td align="left">178 bp</td>
                <td align="left">TACTGAAAAAGGGCCAGTAG</td>
                <td align="left">52Â°C</td>
              </tr>
              <tr>
                <td/>
                <td/>
                <td/>
                <td/>
                <td/>
                <td/>
              </tr>
              <tr>
                <td align="left">TÎ²RII, human</td>
                <td align="left">435â454</td>
                <td align="left">5-HTBR2B</td>
                <td align="left">274 bp</td>
                <td align="left">CGCGTATCGCCAGCACGATC</td>
                <td align="left">63Â°C</td>
              </tr>
              <tr>
                <td align="left">(<ext-link ext-link-type="gen" xlink:href="NM_003242">NM_003242</ext-link>)</td>
                <td align="left">688â708</td>
                <td align="left">3-HTBR2B</td>
                <td align="left">349 bp</td>
                <td align="left">TGGTAGGGGAGCTTGGGGTCA</td>
                <td/>
              </tr>
              <tr>
                <td align="left">(<ext-link ext-link-type="gen" xlink:href="NM_001024847">NM_001024847</ext-link>)</td>
                <td align="left">795â815</td>
                <td align="left">5-HTBR2E3</td>
                <td align="left">298 bp</td>
                <td align="left">GTAGCTCTGATGAGTGCAATG</td>
                <td align="left">60Â°C</td>
              </tr>
              <tr>
                <td/>
                <td align="left">1072â1092</td>
                <td align="left">3-HTBR2E4</td>
                <td align="left">406 bp</td>
                <td align="left">TGGTTGATGTTGTTGGCACAC</td>
                <td/>
              </tr>
              <tr>
                <td align="left">TÎ²RIIC, human</td>
                <td align="left">89â108</td>
                <td align="left">5-HTBR2Z</td>
                <td align="left">319 bp</td>
                <td align="left">GGAGCACTTGTCAAAACACTG</td>
                <td align="left">57Â°C</td>
              </tr>
              <tr>
                <td align="left">(<ext-link ext-link-type="gen" xlink:href="AJ786388">AJ786388</ext-link>)</td>
                <td align="left">84â115</td>
                <td align="left">3-HTBR2CD</td>
                <td align="left">115 bp</td>
                <td align="left">TCCCAGCCAGTGTTTTGACAAG</td>
                <td align="left">60Â°C</td>
              </tr>
              <tr>
                <td/>
                <td/>
                <td/>
                <td/>
                <td/>
                <td/>
              </tr>
              <tr>
                <td align="left">TÎ²RIII, human</td>
                <td align="left">2501â2520</td>
                <td align="left">5-HTBR3E13</td>
                <td align="left">217 bp</td>
                <td align="left">TGTGTGCCTCCTGACGAAGC</td>
                <td align="left">59Â°C</td>
              </tr>
              <tr>
                <td align="left">(<ext-link ext-link-type="gen" xlink:href="NM_003243">NM_003243</ext-link>)</td>
                <td align="left">2609â2717</td>
                <td align="left">3-HTBR3E15</td>
                <td/>
                <td align="left">AGGCTGCAAACGCAATGCCC</td>
                <td/>
              </tr>
              <tr>
                <td colspan="6">
                  <hr/>
                </td>
              </tr>
              <tr>
                <td align="left">TGF-Î²1, human</td>
                <td align="left">1402â1420</td>
                <td align="left">5-HTGFB1E3</td>
                <td align="left">426 bp</td>
                <td align="left">TGGCGATACCTCAGCAACC</td>
                <td align="left">55Â°C</td>
              </tr>
              <tr>
                <td align="left">(<ext-link ext-link-type="gen" xlink:href="NM_000660">NM_000660</ext-link>)</td>
                <td align="left">1809â1827</td>
                <td align="left">3-HTGFB1E6</td>
                <td/>
                <td align="left">GTTGGCATGGTAGCCCTTG</td>
                <td/>
              </tr>
              <tr>
                <td/>
                <td/>
                <td/>
                <td/>
                <td/>
                <td/>
              </tr>
              <tr>
                <td align="left">TGF-Î²2, human</td>
                <td align="left">680â699</td>
                <td align="left">5-HTB2CP</td>
                <td align="left">185 bp</td>
                <td align="left">CAACAGCACCAGGGACTTGC</td>
                <td align="left">65Â°C</td>
              </tr>
              <tr>
                <td align="left">(<ext-link ext-link-type="gen" xlink:href="M19154">M19154</ext-link>)</td>
                <td align="left">845â864</td>
                <td align="left">3-HTB2CP</td>
                <td/>
                <td align="left">AGCACAAGCTGCCCACTGAG</td>
                <td/>
              </tr>
              <tr>
                <td align="left">(<ext-link ext-link-type="gen" xlink:href="NM_003238">NM_003238</ext-link>)</td>
                <td align="left">658â679</td>
                <td align="left">5-TGFB2E1B</td>
                <td align="left">272 bp</td>
                <td align="left">CCCCGGAGGTGATTTCCATCTA</td>
                <td align="left">62Â°C</td>
              </tr>
              <tr>
                <td/>
                <td align="left">908â929</td>
                <td align="left">3-TGFB2E1B</td>
                <td align="left">188 bp</td>
                <td align="left">GTAGGGTCTGTAGAAAGTGGGC</td>
                <td/>
              </tr>
              <tr>
                <td/>
                <td/>
                <td/>
                <td/>
                <td/>
                <td/>
              </tr>
              <tr>
                <td align="left">TGF-Î²3, human</td>
                <td align="left">342â361</td>
                <td align="left">5-TGFB3E1</td>
                <td align="left">332 bp</td>
                <td align="left">TGGACTTCGGCCACATCAAG</td>
                <td align="left">57Â°C</td>
              </tr>
              <tr>
                <td align="left">(<ext-link ext-link-type="gen" xlink:href="NM_003239">NM_003239</ext-link>)</td>
                <td align="left">653â673</td>
                <td align="left">3-TGFB3E2</td>
                <td/>
                <td align="left">CTCCACTGAGGACACATTGAA</td>
                <td/>
              </tr>
              <tr>
                <td colspan="6">
                  <hr/>
                </td>
              </tr>
              <tr>
                <td align="left">GAPDH<sup>d</sup>, human</td>
                <td align="left">402-421</td>
                <td align="left">5-GAPDH</td>
                <td align="left">300 bp</td>
                <td align="left">CGTCTTCACCACCATGGAGA</td>
                <td align="left">59Â°C</td>
              </tr>
              <tr>
                <td align="left">(<ext-link ext-link-type="gen" xlink:href="NM_002046">NM_002046</ext-link>)</td>
                <td align="left">682-701</td>
                <td align="left">3-GAPDH</td>
                <td/>
                <td align="left">CGGCCATCACGCCACAGTTT</td>
                <td/>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <p><sup><italic>a</italic></sup>Acc No, EMBL/DDBJ/GenBank Accession Number</p>
            <p><sup><italic>b</italic></sup>AT, annealing temperature</p>
            <p><sup><italic>c</italic></sup>this position is equivalent to 1â20 in <ext-link ext-link-type="gen" xlink:href="AJ619019">AJ619019</ext-link></p>
            <p><sup><italic>d</italic></sup>GAPDH, glyceraldehyde-3-phosphate dehydrogenase</p>
          </table-wrap-foot>
        </table-wrap>
      </sec>
      <sec>
        <title>Alternative splicing and mRNA expression of TÎ²RII</title>
        <p>An alternatively spliced exon between the first two exons of the TÎ²RII gene was described for mouse and human [<xref ref-type="bibr" rid="B28">28</xref>-<xref ref-type="bibr" rid="B30">30</xref>] (Fig. <xref ref-type="fig" rid="F2">2AâC</xref>). The cassette type exon 2B consists of 75 bp and codes for 25 amino acids. Due to admission of exon 2B amino acid exchange occurs at the splice site junction between both receptor variants, from isoleucine to valine in human and from phenylalanine to valine in the mouse sequence (Fig. <xref ref-type="fig" rid="F2">2B,C</xref>). Exon 2B shows 14 nucleotide exchanges between the human and mouse sequence coding for 7 different amino acids. In contrast the nucleotide and amino acid sequence from Pan troglodytes is 100% identical to human, whereas the nucleotide sequence from Macaca mulatta demonstrated two different nucleotides, thus resulting in one amino acid exchange.</p>
        <fig position="float" id="F2">
          <label>Figure 2</label>
          <caption>
            <p>(<bold>A</bold>) Schematic drawing of the TÎ²RII protein (EC, extracellular domain; TM, transmembrane domain; Kinase, Ser/Thr kinase domain) with the two alternatively spliced exons 2B and 4B. (<bold>B</bold>) Nucleotide sequence of the cDNA and deduced amino acid sequence of exon 2B (underlined capital letters) and splice site junctions (lower case letters) of the variant TÎ²RIIB are shown. (<bold>C</bold>) Additionally, the partial nucleotide and amino acid sequence of TÎ²RII without exon 2B is shown. Underlined amino acids indicate amino acid exchange at the splice site junction due to the alternative splicing. Bold letters mark the amino acid and nucleotide exchanges with respect to the human sequence. Arrows indicate the exon boundaries. (hs, homo sapiens; pt, pan troglodytes; mmu, macaca mulatta; mm, mus musculus).</p>
          </caption>
          <graphic xlink:href="1471-2164-8-318-2"/>
        </fig>
        <p>The alignment of the ESTs with the genomic sequence revealed the novel transcript TÎ²RIIC (Acc. No. <ext-link ext-link-type="gen" xlink:href="AJ786388">AJ786388</ext-link>) with the alternatively spliced exon 4B comprising 108 nucleotides arranged in frame and encoding 36 amino acids (Fig. <xref ref-type="fig" rid="F3">3</xref>). Exon 4B belongs to the cassette type of exons and is part of the extracellular domain of the receptor (Fig. <xref ref-type="fig" rid="F2">2A</xref>). The nucleotide and amino acid sequence from Pan troglodytes demonstrated one different nucleotide thus resulting in one different amino acid, whereas the nucleotide sequence from Macaca mulatta demonstrated 7 different nucleotides, thus resulting in 5 amino acid exchanges compared with the human sequence (Fig. <xref ref-type="fig" rid="F3">3</xref>).</p>
        <fig position="float" id="F3">
          <label>Figure 3</label>
          <caption>
            <p>Nucleotide and amino acid sequence of exon 4B (underlined capital letters) of the variant TÎ²RIIC and TÎ²RIICÎ4 are given. Furthermore, the partial nucleotide and amino acid sequences of TÎ²RII without exon 4B are shown. Bold letters mark the amino acid and nucleotide exchanges with respect to the human sequence. Arrows indicate the exon boundaries. (hs, homo sapiens; pt, pan troglodytes; mmu, macaca mulatta).</p>
          </caption>
          <graphic xlink:href="1471-2164-8-318-3"/>
        </fig>
        <p>The alternatively spliced exon 2B was found in the human EST database (e.g. BG898778, Fig. <xref ref-type="fig" rid="F4">4A</xref>). We also analyzed the truncated TÎ²RII sequence provided by Yang et al. [<xref ref-type="bibr" rid="B35">35</xref>] and found that it was identical to exon 1 and exon 2 and some nucleotides in the 3'-UTR, thus resulting in a truncated receptor isoform as published (Fig. <xref ref-type="fig" rid="F4">4A</xref>). Additionally, only one EST for TÎ²RIIC could be identified (Fig. <xref ref-type="fig" rid="F4">4A</xref>). Expression of TÎ²RII and TÎ²RIIB was apparent in the prostate cells hPCPs, PC-3 and LNCaP (Fig. <xref ref-type="fig" rid="F4">4B</xref>). In contrast to the weak expression of TÎ²RIB compared to TÎ²RI, the long variant TÎ²RIIB is as strongly expressed as TÎ²RII. Because TÎ²RIIC was very weakly expressed in the prostatic cell lines and the EST BG955255 was derived from colon tissue, we also analyzed the colon cancer cells Caco-2. With nested RT-PCR, mRNA expression could be detected in Caco-1, PC-3 and hPCPs, but only very weakly in LNCaP cells (Fig. <xref ref-type="fig" rid="F4">4B</xref>). Despite the low expression, we found mRNA expression in up to 20 normal tissues (Fig. <xref ref-type="fig" rid="F4">4B</xref>). Furthermore, we identified an aberrant splicing pattern at the 5'-end of the alternative exon of TÎ²RIIC, where an alternative AG was used for splicing (Fig. <xref ref-type="fig" rid="F4">4C</xref>), resulting in a preliminary stop codon (Fig. <xref ref-type="fig" rid="F3">3</xref>). Although expression of TÎ²RIICÎ4 was low compared to TÎ²RIIC (Fig. <xref ref-type="fig" rid="F4">4C</xref>), it was apparent in all cell lines and tissues studied.</p>
        <fig position="float" id="F4">
          <label>Figure 4</label>
          <caption>
            <p>(<bold>A</bold>) Comparison of the exon structure of the human TÎ²RII mRNA with the truncated sequence provided by Yang et al. [35]. Lines depict the 5'-UTR, 3'-UTR and ESTs with additional exons. (<bold>B</bold>) Expression pattern of both transcript variants of the TÎ²RII gene in human prostatic cells (upper panel, 5-HTBR2B/3-HTBR2B). Expression of the novel splice variant TÎ²RIIC in human prostatic cells (lower panel, nested PCR first round 5-HTBR2E3/3-HTBR2E4, second round 5-HTBR2Z/3-HTBR2E4) and normal human tissues (5-HTBR2E3/3-HTBR2CD) is shown. Additionally, GAPDH expression is also provided. (<bold>C</bold>) Fluorescence detection of TÎ²RIICÎ4 (5-HTBR2E3/3-HTBR2CD, arrows) and TÎ²RIIC is demonstrated. Caco, Caco-2; ctrl, control; g, gland; m, muscle; mu, mucosa; s, small; ma, marrow.</p>
          </caption>
          <graphic xlink:href="1471-2164-8-318-4"/>
        </fig>
      </sec>
      <sec>
        <title>Alternative splicing and mRNA expression of TÎ²RIII (betaglycan)</title>
        <p>The alignment of the ESTs for TÎ²RIII with the genomic sequence did not reveal additional exons. All prostatic cells expressed mRNA of the TÎ²RIII (Fig. <xref ref-type="fig" rid="F5">5A</xref>).</p>
        <fig position="float" id="F5">
          <label>Figure 5</label>
          <caption>
            <p>(<bold>A</bold>) Exon structure of the human TÎ²RIII (betaglycan) mRNA. Lines depict the 5'-UTR and 3'-UTR. Expression pattern of the TÎ²RIII gene in human prostatic cells (5-HTBR3E13/3-HTBR3E15). (<bold>B</bold>) Exon structure of the human TGF-Î²1 mRNA. Lines depict the 5'-UTR and 3'-UTR. Expression pattern of the TGF-Î²1 gene in human prostatic cells (5-HTGFB1E3/3-HTGFB1E6). Ctrl, control.</p>
          </caption>
          <graphic xlink:href="1471-2164-8-318-5"/>
        </fig>
      </sec>
      <sec>
        <title>Alternative splicing and mRNA expression of TGF-Î²1</title>
        <p>The alignment of the TGF-Î²1 gene with the ESTs did not show any new exons. Because in the TGF-Î²2 gene the alternatively spliced exon 2B between the first two exons was found as mentioned above, we tested whether this was also the case for the TGF-Î²1 cDNA. However, in the prostatic cells no additional exon was identified (data not shown). Besides LNCaP all cell lines studied showed expression of TGF-Î²1 (Fig. <xref ref-type="fig" rid="F5">5B</xref>). Additionally, we tested whether exons 4 and 5 were deleted in the human sequence as has been published for the porcine sequence [<xref ref-type="bibr" rid="B24">24</xref>]. However, in the prostatic cell lines studied this deletion was not detectable (Fig. <xref ref-type="fig" rid="F5">5B</xref>).</p>
      </sec>
      <sec>
        <title>Alternative splicing and mRNA expression of TGF-Î²2</title>
        <p>For the TGF-Î²2 gene an additional cassette type exon between exons 1 and 2 was published for man and rat [<xref ref-type="bibr" rid="B12">12</xref>,<xref ref-type="bibr" rid="B25">25</xref>] and is now also available for monkeys, dogs, rabbits and mice (Fig. <xref ref-type="fig" rid="F6">6</xref>). The coding sequence is 84 bp in all species, resulting in additional 28 amino acids with a change from asparagine to aspartic acid in TGF-Î²2B at the splice site (Fig. <xref ref-type="fig" rid="F6">6</xref>). Nucleotide and amino acid sequences of TGF-Î²2B of the different species are more closely related to the human sequence than these of TÎ²RIIC or TÎ²RIIB. For example, the nucleotide and amino acid sequence of TGF-Î²2B from Pan troglodytes and Macaca mulatta is 100% identical to the human sequence (Fig. <xref ref-type="fig" rid="F6">6</xref>), whereas the nucleotide sequence of TÎ²RIIC from Pan troglodytes and Macaca mulatta is only 99.1% and 93.5%, respectively, identical to the human sequence (Fig. <xref ref-type="fig" rid="F3">3</xref>).</p>
        <fig position="float" id="F6">
          <label>Figure 6</label>
          <caption>
            <p>Schematic drawing of the TGF-Î²2 protein (LAP, latency-associated peptide) with the alternatively spliced exon 2B. Nucleotide and amino acid sequence of exon 2B (underlined capital letters) of the variant TGF-Î²2B are shown. Additionally, the partial sequence of TGF-Î²2 without exon 2B is shown. The sequence of TGF-Î²2 was not available for oryctolagus cuniculus. Underlined amino acids indicate amino acid exchange at the splice site junction due to the alternative splicing. Bold letters mark the amino acid and nucleotide exchanges with respect to the human sequence. Arrows indicate the exon boundaries. The accession numbers are also given. (hs, homo sapiens; pt, pan troglodytes; mmu, macaca mulatta; cf, canis familiaris; oc, oryctolagus cuniculus; mm, mus musculus; rn, rattus norvegicus).</p>
          </caption>
          <graphic xlink:href="1471-2164-8-318-6"/>
        </fig>
        <p>The alignment of the ESTs coding for TGF-Î²2 with the genomic sequence showed the EST BF725669 to contain an additional exon (Fig. <xref ref-type="fig" rid="F7">7A</xref>). The alternatively spliced TGF-Î²2B and TGF-Î²2 are expressed in PC-3 and hPCPs cells, but expression of TGF-Î²2B was weaker in comparison to TGF-Î²2 (Fig. <xref ref-type="fig" rid="F7">7B</xref>).</p>
        <fig position="float" id="F7">
          <label>Figure 7</label>
          <caption>
            <p>(<bold>A</bold>) Comparison of the exon structure of the human TGF-Î²2 mRNA with the ESTs BP214137 and BF752669 containing the additional alternative exon 2B. Lines depict the 5'-UTR, 3'-UTR and introns. (<bold>B</bold>) Expression of both transcript variants (upper panel, 5-TGFB2E1B/3-TGFB2E2B) and expression of the splice variant TGF-Î²2B (lower panel; 5-HTB2CP/3-HTB2CP) is shown. (<bold>C</bold>) Exon structure of the human TGF-Î²3 mRNA. Lines depict the 5'-UTR and 3'-UTR. (<bold>D</bold>) Expression pattern of the TGF-Î²3 gene in human prostatic cells (left panel, 5-TGFB3E1/3-TGFB3E2). Additionally, GAPDH expression of all cell lines studied is shown. Ctrl, control.</p>
          </caption>
          <graphic xlink:href="1471-2164-8-318-7"/>
        </fig>
      </sec>
      <sec>
        <title>Alternative splicing and mRNA expression of TGF-Î²3</title>
        <p>The alignment of the TGF-Î²3 cDNA sequence with the EST database only yielded incorrectly spliced exons (Fig. <xref ref-type="fig" rid="F7">7C</xref>). We found an annotation for alternative splicing of TGF-Î²3 in the ASDB database [<xref ref-type="bibr" rid="B22">22</xref>]. Although the TGF-Î²3 gene could be found in this genomic clone, the alternative splicing does belong to the next gene, adjacent to TGF-Î²3. mRNA expression of TGF-Î²3 was investigated with primers located in exon 1 and exon 2 to test for possible new exons. However, we only observed one specific amplicon in all prostatic cell lines except for LNCaP cells (Fig. <xref ref-type="fig" rid="F7">7D</xref>).  Expression of the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH) for all cell lines used is shown in Fig. <xref ref-type="fig" rid="F7">7D</xref>. </p>
      </sec>
      <sec>
        <title>Localization of the alternative splice variants</title>
        <p>Localization of the splice variant TÎ²RIIB was found mainly in the basal cells but also in the columnar cells of the epithelium of nontumorous glands and is shown exemplarily for a prostate carcinoma patient with histological grading pT3apN0M0 (Fig. <xref ref-type="fig" rid="F8">8A</xref>). However, staining was also found in epithelial cells in tumorous glands (data not shown). The negative control without the primary antibody did not show any staining (Fig. <xref ref-type="fig" rid="F8">8B</xref>).</p>
        <fig position="float" id="F8">
          <label>Figure 8</label>
          <caption>
            <p>(<bold>A</bold>) Localization of TÎ²RIIB in human prostate carcinoma is found in most epithelial cells (mainly in basal but also in columnar cells) in a nontumorous gland adjacent to a nontumorous gland without staining. (<bold>B) </bold>The negative control did not reveal any staining. Localization of TÎ²RIIC in human prostate carcinoma was found in epithelial cells (<bold>C</bold>) and muscle cells (<bold>D</bold>). TGF-Î²2B was localized primarily in the apical region of epithelial cells (<bold>E</bold>). (<bold>F</bold>) The negative control did not reveal any staining. A-F, 100Ã magnification</p>
          </caption>
          <graphic xlink:href="1471-2164-8-318-8"/>
        </fig>
        <p>TÎ²RIIC was localized in the epithelial cells (Fig. <xref ref-type="fig" rid="F8">8C</xref>) in very few glands of the human prostate (histological grading pT2apN0M0) and also in muscle cells (Fig. <xref ref-type="fig" rid="F8">8D</xref>, histological grading pT3bpN0M0). The splice variant TGF-Î²2B was found also mainly in the epithelial cells in the apical region (Fig. <xref ref-type="fig" rid="F8">8E</xref>, histological grading pT2bpN0M0). The negative control without the primary antibody did not show any staining (Fig. <xref ref-type="fig" rid="F8">8F</xref>).</p>
      </sec>
      <sec>
        <title>Functional analysis of the alternative splice variants</title>
        <p>We used a sensitive ELISA to determine the amounts of plasminogen activator inhibitor-1 (PAI-1) in the supernatant of PC-3 cells which are known to secrete PAI-1 [<xref ref-type="bibr" rid="B36">36</xref>]. Stimulation of PC-3 cells with 10 ng/ml recombinant TGF-Î²2 demonstrated a highly significant approximately 10-fold increase in PAI-1 secretion compared to the unstimulated control (Fig. <xref ref-type="fig" rid="F9">9</xref>). Antibody perturbation experiments performed with three different antibodies against TÎ²RII, TÎ²RIIB and TÎ²RIIC showed a significant reduction (approximately 30%) in secretion of PAI-1 only for the anti-TÎ²RII antibodies compared to the stimulation with TGF-Î²2 (Fig. <xref ref-type="fig" rid="F9">9</xref>). Although antibodies against TÎ²RIIB and TÎ²RIIC demonstrated a reduction of 14% and 21%, respectively, in PAI-1 secretion, the effects were not significant.</p>
        <fig position="float" id="F9">
          <label>Figure 9</label>
          <caption>
            <p>Secretion of PAI-1 by PC-3 cells was quantified by ELISAs. TGF-Î²2 alone (-) stimulated secretion of PAI-1 significantly compared to the control (Ctrl). Antibody perturbation experiments with antibodies specific for the extracellular domains of TÎ²RII (RII), the alternative exons of TÎ²RIIB (RIIB) and TÎ²RIIC (RIIC), demonstrated a significant decrease in the amount of PAI-1 only for TÎ²RII compared to the stimulation with TGF-Î²2 (-) or the unspecific antibody (ctrl-R). For the sake of clarity, we have not indicated that the antibody perturbation experiments were also significantly different to the control (Ctrl) without any TGF-Î²2 treatment. An unspecific antibody (ctrl-R) did not inhibit PAI-1 secretion stimulated by TGF-Î²2. Each experiment was independently repeated five times (n = 5) in duplicate, with each value given as the mean Â± SEM. Statistically significant differences are indicated (*, <italic>P </italic>&lt; 0.05; ***, <italic>P </italic>&lt; 0.001).</p>
          </caption>
          <graphic xlink:href="1471-2164-8-318-9"/>
        </fig>
      </sec>
    </sec>
    <sec>
      <title>Discussion</title>
      <p>We have analyzed the mRNA expression of the TGF-betas and their respective high-affinity receptors in human prostatic cells available to us and identified alternative splicing in TÎ²RI, TÎ²RII and TGF-Î²2 (Table <xref ref-type="table" rid="T2">2</xref>). It is striking that the alternatively spliced exons are located in the N-terminal part of the proteins, whereby in both receptors the additional amino acids were part of the extracellular domain. Also, the novel isoform TÎ²RIIC is characterized by 36 additional amino acids in the extracellular domain. Up to date, the variant TGF-Î²2B is sequenced in more species and showed less sequence variations than TÎ²RIIB and TÎ²RIIC. Additionally, we demonstrated that the splice variants are translated and found a preferential epithelial localization in the human prostate. For the first time we could show that stimulation of PC-3 cells with TGF-Î²2 resulted in a significant and strong increase in secretion of PAI-1 with a major participation of TÎ²RII and to a lesser extent that of TÎ²RIIB and TÎ²RIIC.</p>
      <table-wrap position="float" id="T2">
        <label>Table 2</label>
        <caption>
          <p>Expression pattern of the TGF-Î² ligands, receptors and splice variants</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead>
            <tr>
              <td/>
              <td align="center">hPCPs</td>
              <td align="center">LNCaP</td>
              <td align="center">PC-3</td>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td align="left">
                <bold>Ligands</bold>
              </td>
              <td/>
              <td/>
              <td/>
            </tr>
            <tr>
              <td align="left">TGF-Î²1</td>
              <td align="center">+</td>
              <td align="center">-</td>
              <td align="center">+</td>
            </tr>
            <tr>
              <td align="left">TGF-Î²2</td>
              <td align="center">+</td>
              <td align="center">-</td>
              <td align="center">+</td>
            </tr>
            <tr>
              <td align="left">TGF-Î²3</td>
              <td align="center">+</td>
              <td align="center">-</td>
              <td align="center">+</td>
            </tr>
            <tr>
              <td colspan="4">
                <hr/>
              </td>
            </tr>
            <tr>
              <td align="left">
                <bold>Receptors</bold>
              </td>
              <td/>
              <td/>
              <td/>
            </tr>
            <tr>
              <td align="left">TÎ²RI</td>
              <td align="center">+</td>
              <td align="center">+</td>
              <td align="center">+</td>
            </tr>
            <tr>
              <td align="left">TÎ²RII</td>
              <td align="center">+</td>
              <td align="center">+</td>
              <td align="center">+</td>
            </tr>
            <tr>
              <td align="left">TÎ²RIII</td>
              <td align="center">+</td>
              <td align="center">+</td>
              <td align="center">+</td>
            </tr>
            <tr>
              <td colspan="4">
                <hr/>
              </td>
            </tr>
            <tr>
              <td align="left">
                <bold>Splice variants</bold>
              </td>
              <td/>
              <td/>
              <td/>
            </tr>
            <tr>
              <td align="left">TÎ²RIB</td>
              <td align="center">+</td>
              <td align="center">+</td>
              <td align="center">-</td>
            </tr>
            <tr>
              <td align="left">TÎ²RIIB</td>
              <td align="center">+</td>
              <td align="center">+</td>
              <td align="center">+</td>
            </tr>
            <tr>
              <td align="left">TÎ²RIIC</td>
              <td align="center">+</td>
              <td align="center">-</td>
              <td align="center">+</td>
            </tr>
            <tr>
              <td align="left">TGF-Î²2B</td>
              <td align="center">+</td>
              <td align="center">-</td>
              <td align="center">+</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <sec>
        <title>mRNA Expression of prostatic TGF-betas and their receptors</title>
        <p>Analysis of mRNA expression of TGF-betas and their receptors in human prostatic cell lines showed very controversial results. It is generally accepted that PC-3 cells express TGF-Î²1, TGF-Î²2 and TGF-Î²3 [<xref ref-type="bibr" rid="B37">37</xref>,<xref ref-type="bibr" rid="B38">38</xref>] and even more the TGF-Î²2 gene was originally cloned from PC-3 cells [<xref ref-type="bibr" rid="B12">12</xref>]. In line with this, our study also showed expression of all TGF-beta ligands in the stromal hPCPs and PC-3. However, experiments with LNCaP yielded controversial results. Whereas mRNA expression for TGF-Î²1 to TGF-Î²3 was demonstrated [<xref ref-type="bibr" rid="B37">37</xref>] all other studies including this one could not find mRNA expression of TGF-Î²1 in LNCaP cells [<xref ref-type="bibr" rid="B39">39</xref>,<xref ref-type="bibr" rid="B40">40</xref>]. Our study showed expression of all TGF-beta ligands in the stromal cells hPCPs which is in accordance with the results for other stromal cell lines derived from the human prostate [<xref ref-type="bibr" rid="B41">41</xref>]. However, this study confirmed an earlier report showing that PC-3 cells express the splice variant TGF-Î²2B [<xref ref-type="bibr" rid="B12">12</xref>].</p>
        <p>PC-3 cells showed expression of TÎ²RI and TÎ²RII, which was confirmed in this study. In LNCaP cells expression of TÎ²RII was found, but TÎ²RI was not expressed [<xref ref-type="bibr" rid="B42">42</xref>,<xref ref-type="bibr" rid="B43">43</xref>]. However, another study [<xref ref-type="bibr" rid="B44">44</xref>] like the present detected mRNA expression by RT-PCR in LNCaP cells. For stromal prostatic cells expression of TÎ²RI and TÎ²RII was found by us and others [<xref ref-type="bibr" rid="B45">45</xref>]. This is the first study to show expression of TÎ²RIII and the receptor splice variants TÎ²RIB and TÎ²RIIB and to identify a novel transcript termed TÎ²RIIC which will be discussed below. Only the stromal cells hPCPs expressed all receptor splice variants as well as TGF-Î²2B (Table <xref ref-type="table" rid="T2">2</xref>). Except for the splice variant TÎ²RIB, PC-3 cells also expressed all receptor splice variants, whereas LNCaP cells did not express TGF-Î²2B which is in line with the missing expression of all TGF-Î² ligands. Interestingly, these cells did also not express the newly identified splice variant TÎ²RIIC (Table <xref ref-type="table" rid="T2">2</xref>).</p>
      </sec>
      <sec>
        <title>Localization and protein data of the splice variants of TGF-Î² ligands and receptors</title>
        <p>Agrotis et al. [<xref ref-type="bibr" rid="B30">30</xref>] have demonstrated, that TÎ²RI is more abundant in contractile smooth muscle cells than the variant TÎ²RIB. Additionally, they found that TÎ²RI displayed a greater ability to induce PAI-1 mRNA in response to TGF-Î²1, whereas TÎ²RIB performed slightly better in growth inhibition [<xref ref-type="bibr" rid="B30">30</xref>]. Interestingly, we identified for TÎ²RI a pseudogene on chromosome 19, reaching from exon 2 to exon 4 and a short stretch of 62 bp from the 3'-UTR of the gene.</p>
        <p>In contrast to TÎ²RI which mainly is important for signal transduction, TÎ²RII is involved in direct interaction with the ligands TGF-Î²1, TGF-Î²2 and TGF-Î²3 [<xref ref-type="bibr" rid="B1">1</xref>]. In TÎ²RII the additional exon 2B was hypothesized to be involved in high-affinity binding of TGF-Î²2 to the receptor isoform TÎ²RIIB also in the absence of TÎ²RIII [<xref ref-type="bibr" rid="B10">10</xref>]. However, it was shown recently that TGF-Î²2 could bind to soluble TÎ²RIIB or TÎ²RII only in combination with soluble TÎ²RI [<xref ref-type="bibr" rid="B46">46</xref>] and that also TGF-Î²1 could interact with TÎ²RIIB [<xref ref-type="bibr" rid="B11">11</xref>]. Furthermore, the TÎ²R knockouts, TÎ²RI [<xref ref-type="bibr" rid="B47">47</xref>], TÎ²RII [<xref ref-type="bibr" rid="B48">48</xref>] and TÎ²RIII [<xref ref-type="bibr" rid="B49">49</xref>], revealed non-overlapping phenotypes with the TGF-Î²2 null mice [<xref ref-type="bibr" rid="B5">5</xref>], although TÎ²RIII knockouts displayed reduced TGF-Î²2 binding [<xref ref-type="bibr" rid="B49">49</xref>]. This implies that either the high-affinity receptor for TGF-Î²2 is still not found or that receptor combinations might be responsible for the interaction.</p>
        <p>Expression of TÎ²RII was found in the human prostate in normal and tumor tissue primarily in the epithelial cells with a diminished expression in more advanced stages [<xref ref-type="bibr" rid="B16">16</xref>]. Similarily our results with TÎ²RIIB also showed a distinct localization in the epithelial cells of normal and tumor tissue of the human prostate.</p>
        <p>Our analysis clearly showed the expression of a novel transcript variant TÎ²RIIC in PC-3, hPCPs cells, Caco-2 and up to 20 normal tissues including human prostate, indicating a ubiquitous expression in human organs. The additional and alternatively spliced exon encodes 36 amino acids located in the extracellular domain in close proximity to the transmembrane domain. Although the database search for protein domains revealed no similarities to other proteins or specific motifs, it is noteworthy, that the additional domain contains two additional cysteines which might be important for protein folding. Interestingly, we found a deletion of 4 bp at the 5'-end of the additional exon 4B in TÎ²RIICÎ4, possibly resulting in a truncated receptor. Although expressed at a very low level, it was found in normal tissue and preliminary results suggest this to be also the case in tumor samples. Interestingly protein localization of TÎ²RIIC was also found mainly in the epithelial cells of the human prostate but in very few glands.</p>
        <p>The splice variant TGF-Î²2B mRNA was first described in the prostatic cell line PC-3 [<xref ref-type="bibr" rid="B12">12</xref>,<xref ref-type="bibr" rid="B50">50</xref>] and in rats in skeletal muscles, aorta, primary bronchus, heart, uterus, sciatic nerve, and spinal cord [<xref ref-type="bibr" rid="B25">25</xref>]. Additionally, TGF-Î²2B mRNA and protein were found in most somatic and germinal cells of mouse and rat [<xref ref-type="bibr" rid="B51">51</xref>]. TGF-Î²2B was also demonstrated to be secreted by BSC-40 cells from monkeys [<xref ref-type="bibr" rid="B52">52</xref>]. The additional exon of TGF-Î²2B is part of the LAP-domain which is important for correct secretion and inactivation of the mature C-terminal TGF-Î²2 dimer [<xref ref-type="bibr" rid="B8">8</xref>]. The alternatively spliced exon 2B contains 3 additional cysteine residues which might be important for the formation of cysteine bonds and therefore might influence protein folding. However, TGF-Î²2B is secreted and forms a latent complex with the LAP [<xref ref-type="bibr" rid="B52">52</xref>]. It is important to note that TGF-Î²2B is cleaved similarly to TGF-Î²2 and yields a mature monomer/dimer of exactly the same size as mature TGF-Î²2 [<xref ref-type="bibr" rid="B52">52</xref>]. Because only mature TGF-Î²2 binds to the receptor it is equal whether mature TGF-Î²2 is cleaved from the short TGF-Î²2 variant or long TGF-Î²2B variant. Whether the existence of the two different TGF-Î²2 LAP complexes is required for different binding to LTBPs and thus might be stored differently in the ECM warrants further investigation.</p>
        <p>Up to date TGF-Î²2B was identified in most species, whereas TÎ²RIB and TÎ²RIIB were found in fewer species. It is noteworthy that TÎ²RIIB is not as well conserved between human and mouse than TGF-Î²2B and up to date was not found in rat [<xref ref-type="bibr" rid="B51">51</xref>]. Therefore, we conclude that TÎ²RIIB is not as ubiquitously expressed in the different species like the other variants and therefore could not serve as a ubiquitous receptor for TGF-Î²2. In line with this assumption, we could observe only a moderate decrease in PAI-1 secretion after inhibition of TÎ²RIIB or TÎ²RIIC after stimulation of PC-3 cells with TGF-Î²2. However, this is the first report showing a 10-fold increase of PAI-1 secretion in PC-3 cells after stimulation with TGF-Î²2.</p>
      </sec>
    </sec>
    <sec>
      <title>Conclusion</title>
      <p>In general, mRNA expression of the TGF-Î² and TÎ²R splice variants was more heterogeneous and weaker compared to the variants without the alternative exons. The variant TGF-Î²2B was identified in most species and is up to date the best conserved isoform among the various species. Similarly, the splice variant TÎ²RIB was also found in many species in contrast to the isoforms TÎ²RIIB and TÎ²RIIC which showed a more restricted species distribution. This is the first report showing a distinct localization of TGF-Î²2B, TÎ²RIIB and TÎ²RIIC in the human prostate mainly in the epithelium.</p>
    </sec>
    <sec sec-type="methods">
      <title>Methods</title>
      <sec>
        <title>Cell lines and tissues</title>
        <p>The stromal cells hPCPs from the human prostate were propagated as described [<xref ref-type="bibr" rid="B33">33</xref>]. LNCaP and PC-3 cells were purchased from American Type Culture Collection (ATCC) and cultivated as published [<xref ref-type="bibr" rid="B53">53</xref>]. Colon cancer cell line Caco-2 was purchased from ATCC and kindly provided by Dr W.W. Franke (German Cancer Research Center, Heidelberg, Germany) and kept under standard conditions. Total RNA from 20 normal human tissues was purchased (Becton Dickinson, Heidelberg, Germany).</p>
      </sec>
      <sec>
        <title>RNA isolation, cDNA synthesis and RT-PCR</title>
        <p>Total RNA from the cell lines was isolated with Trizol (Gibco BRL, Karlsruhe, Germany) according to the manufacturer's instructions. Total RNA of Caco-2 cells was isolated using RNAeasy isolation kit (Qiagen, Hilden, Germany) according to manufacturer's protocol. Reverse transcription was performed using 2 Î¼g of total RNA and Omniscript (Qiagen), except for total RNA from Caco-2, which was reverse transcribed as described elsewhere [<xref ref-type="bibr" rid="B54">54</xref>]. Primers used for PCR are denoted in Table <xref ref-type="table" rid="T1">1</xref> and were intron-spanning to overcome genomic contamination. PCR was performed on a Hybaid Omnigene Thermocycler (MWG Biotech, Ebersberg, Germany) using mainly PanScript Taq polymerase (Pansystems, Aidenbach, Germany) as described [<xref ref-type="bibr" rid="B55">55</xref>]. Amplification with the primers 5-TGFB3E1/3-TGFB3E2 was performed with the Platinum Taq Polymerase (Invitrogen, Karlsruhe, Germany) according to the manufacturer's instructions. The first round of the nested PCR to clone TÎ²RIIC was done with the primers 5-HTBR2E3/3-HTBR2E4 from which 20 Î¼l were used for the second round with the primers 5-HTBR2Z/3-HTBR2E4. The other fragment of TÎ² RIIC was also cloned after a nested PCR with the primers 5-HTBR2B/3-HTBR2CD in the first round and primers 5-HTBR2E3/3-HTBR2CD were used for the second round. The nested PCR was performed with the Qiagen Taq DNA Polymerase and solution Q (Qiagen) on a PTC100 cycler (Biozym, Germany). Amplification was carried out for 35 cycles, except for 5-GAPDH/3-GAPDH which was run for 25 cycles and 5-HTBR2E3/HTBR2CD which was run for 30 cycles. After an initial heating to 94Â°C for 4 min, each cycle consisted of denaturing at 94Â°C for 45 sec, annealing at the temperatures indicated in Table <xref ref-type="table" rid="T1">1</xref> for 45 sec and elongation at 72Â°C for 90 sec except for the last extension which lasted 5 min. PCR products were separated on agarose gels, extracted with Qiaex (Qiagen), subcloned into the pCR2.0 vector (Invitrogen) and subsequently sequenced by MWG Biotech and GENterprise (Mainz, Germany). Amplification with the Cy-5 labeled primer 5-HTBR2E3 with the primer 3-HTBR2CD to detect TÎ²RIICÎ4 was performed as described [<xref ref-type="bibr" rid="B56">56</xref>], except that cDNA instead of genomic DNA was used. PCR fragments were separated on 8% polyacrylamide gels [<xref ref-type="bibr" rid="B56">56</xref>].</p>
      </sec>
      <sec>
        <title>Screening for alternatively spliced ESTs</title>
        <p>The exon and intron pattern of the TGF-betas and their receptors was either found in the NCBI sequence database or determined by sequence comparison of the cDNAs with the genomic sequences by using the Blast tool. Each exon of the respective cDNAs was aligned with all available ESTs from human. Then, every EST was aligned with the genomic sequences to find alternatively/incorrectly spliced exons, which were analyzed for standard splice sites (GT-AG at the 5'- and 3'-end, respectively) and for a continuous open reading frame. Only good candidates which fulfilled both criteria were further analyzed by RT-PCR.</p>
      </sec>
      <sec>
        <title>Generation of polyclonal antibodies</title>
        <p>Polyclonal antibodies directed against the peptide SFCSIQSQVLCGYLD of the alternative exon of the rat TGF-Î²2B (Fig. <xref ref-type="fig" rid="F6">6</xref>) and against the peptide IRHIGSNNRLQRSTC of the alternative exon of TÎ²RIIC (Fig. <xref ref-type="fig" rid="F3">3</xref>) were raised in two rabbits respectively according to standard protocols (Coring, Gernsheim, Gemany) as published [<xref ref-type="bibr" rid="B51">51</xref>]. These peptide sequences are highly homologous in most species and did not show any homology to other proteins. Polyclonal antibodies were also affinity-purified on a sepharose column. Specificity of the antibodies was tested in ELISAs (CovAbtest, Coring) and western blots. Negative controls were performed with the preimmune serum and showed no binding.</p>
      </sec>
      <sec>
        <title>Analysis of localization of TÎ²RIIB, TÎ²RIIC and TGF-Î²2B</title>
        <p>Polyclonal antibody against TÎ²RIIB was purchased from R&amp;D Systems (Wiesbaden, Germany) and diluted 1:50 for immunohistochemistry. Polyclonal antisera against TÎ²RIIC and TGF-Î²2B were used at dilutions of 1:50 and 1:100. Negative controls were performed by omitting the primary antibodies. Immunohistochemistry was done with the Envision System from DAKO (Hamburg, Germany) according to the instructions of the manufacturer with DAB staining and HE counterstaining.</p>
      </sec>
      <sec>
        <title>PAI-1 ELISA and antibody perturbation</title>
        <p>Quantitation of PAI-1 was performed with the highly sensitive PAI-1 Antigen ELISA Kit (Technoclone, Vienna, Austria), according to the manufacturer's instructions. PC-3 cells (50,000 cells/well) were seeded on 24-well plates and grown in DMEM (+10% FCS and antibiotics) at 37Â°C and 5% CO<sub>2 </sub>for 24 h. Then, medium was changed to DMEM containing the antibodies against TÎ²RII (diluted 1:12.5, AF-241-NA, R&amp;D Systems), TÎ²RIIB (diluted 1:12.5, AF1300, R&amp;D Systems), and TÎ²RIIC (diluted 1:12.5). Control incubations were performed (i) without antibody, and (ii) by replacement of the antibodies by anti-goat IgG (1:12.5; Invitrogen, Karlsruhe, Germany). After incubation at 37Â°C and 5% CO<sub>2 </sub>for 1 h, TGF-Î²2 (10 ng/ml) was added. The cells were grown at 37Â°C for 72 h and collected supernatants were stored with protease-inhibitors (Complete Mini, Roche, Mannheim, Germany) at -20Â°C until the PAI-1 ELISA was performed.</p>
      </sec>
      <sec>
        <title>Statistics</title>
        <p>All experiments were repeated independently at least three times in duplicate. Values from all experiments were used for calculation of the means and their respective standard errors of the mean (SEM). Statistical tests of one way analysis of variance (ANOVA) followed by the non-parametric test of Kruskal Wallis were used to determine significant differences between different experimental groups and the controls by using GraphPad Instat 3 (GraphPad, San Diego, USA). P values less than 0.05 were considered statistically significant.</p>
      </sec>
    </sec>
    <sec>
      <title>Abbreviations</title>
      <p>Acc No, EMBL/DDBJ/GenBank Accession Number; ANOVA, analysis of variance; AT, annealing temperature; ATCC, American Type Culture Collection; bp, base pairs; Caco, Caco-2; cf, canis familiaris; Ctrl, control; ctrl-R (unspecific antibody); EC, extracellular domain; ECM, extracellular matrix; EST, expressed sequence tag; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; g, gland; hs, homo sapiens; Kinase, Ser/Thr kinase domain; LAP, latency-associated peptide; LTBP, latent TGF-Î² binding protein; m, muscle; ma, marrow; mm, mus musculus; mmu, macaca mulatta; mu, mucosa; oc, oryctolagus cuniculus; PAI-1, plasminogen activator inhibitor-1; pt, pan troglodytes; rn, rattus norvegicus; s, small; SEM, standard error of the mean; ss, sus scrofa; TGF-Î², transforming growth factor-beta; TÎ²R, TGF-beta receptor; TM, transmembrane domain.</p>
    </sec>
    <sec>
      <title>Authors' contributions</title>
      <p>LK was responsible for designing, analyzing, collating and interpreting data and drafting the manuscript. JAS performed the ELISAs and antibody perturbation experiments, MMK, LL and AS the cell culture and immunohistochemistry, EVB and HB the RT-PCR, and GH and RH contributed to the design of the study and to the manuscript. All authors have read and approved the final version.</p>
    </sec>
  </body>
  <back>
    <ack>
      <sec>
        <title>Acknowledgements</title>
        <p>This study was financed by the Deutsche Forschungsgemeinschaft GK533 and the Kulemann-Stiftung of the University of Marburg. We thank Dr GH LÃ¼ers for insightful comments during the preparation of the manuscript and H Kirchner, R Nottelmann and B Lauer for technical assistance.</p>
      </sec>
    </ack>
    <ref-list>
      <ref id="B1">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Derynck</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Akhurst</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Balmain</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>TGF-Î² signaling in tumor suppression and cancer progression</article-title>
          <source>Nat Genet</source>
          <year>2001</year>
          <volume>29</volume>
          <fpage>117</fpage>
          <lpage>129</lpage>
          <pub-id pub-id-type="pmid">11586292</pub-id>
          <pub-id pub-id-type="doi">10.1038/ng1001-117</pub-id>
        </citation>
      </ref>
      <ref id="B2">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shull</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Ormsby</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Kier</surname>
              <given-names>AB</given-names>
            </name>
            <name>
              <surname>Pawlowski</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Diebold</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Yin</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Allen</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Sidman</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Proetzel</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Calvin</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Annunziata</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Doetschmann</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Targeted disruption of the mouse transforming growth factor-Î²1 gene results in multifocal inflammatory disease</article-title>
          <source>Nature</source>
          <year>1992</year>
          <volume>359</volume>
          <fpage>693</fpage>
          <lpage>699</lpage>
          <pub-id pub-id-type="pmid">1436033</pub-id>
          <pub-id pub-id-type="doi">10.1038/359693a0</pub-id>
        </citation>
      </ref>
      <ref id="B3">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kulkarni</surname>
              <given-names>AB</given-names>
            </name>
            <name>
              <surname>Huh</surname>
              <given-names>CG</given-names>
            </name>
            <name>
              <surname>Becker</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Geiser</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Lyght</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Flanders</surname>
              <given-names>KC</given-names>
            </name>
            <name>
              <surname>Roberts</surname>
              <given-names>AB</given-names>
            </name>
            <name>
              <surname>Sporn</surname>
              <given-names>MB</given-names>
            </name>
            <name>
              <surname>Ward</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Karlsson</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Transforming growth factor Î²1 null mutation in mice causes excessive inflammatory response and early death</article-title>
          <source>Proc Natl Acad Sci USA</source>
          <year>1993</year>
          <volume>90</volume>
          <fpage>770</fpage>
          <lpage>774</lpage>
          <pub-id pub-id-type="pmid">8421714</pub-id>
          <pub-id pub-id-type="doi">10.1073/pnas.90.2.770</pub-id>
        </citation>
      </ref>
      <ref id="B4">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dickson</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Martin</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Cousins</surname>
              <given-names>FM</given-names>
            </name>
            <name>
              <surname>Kulkarni</surname>
              <given-names>AB</given-names>
            </name>
            <name>
              <surname>Karlsson</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Akhurst</surname>
              <given-names>RJ</given-names>
            </name>
          </person-group>
          <article-title>Defective haematopoiesis and vasculogenesis in transforming growth factor-Î²1 knock out mice</article-title>
          <source>Development</source>
          <year>1995</year>
          <volume>121</volume>
          <fpage>1845</fpage>
          <lpage>1854</lpage>
          <pub-id pub-id-type="pmid">7600998</pub-id>
        </citation>
      </ref>
      <ref id="B5">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sanford</surname>
              <given-names>LP</given-names>
            </name>
            <name>
              <surname>Ormsby</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Gittenberger-de Groot</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Sariola</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Friedman</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Boivin</surname>
              <given-names>GP</given-names>
            </name>
            <name>
              <surname>Cardell</surname>
              <given-names>EL</given-names>
            </name>
            <name>
              <surname>Doetschman</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>TGFÎ²2 knockout mice have multiple developmental defects that are non-overlapping with other TGFÎ² knockout phenotypes</article-title>
          <source>Development</source>
          <year>1997</year>
          <volume>124</volume>
          <fpage>2659</fpage>
          <lpage>2670</lpage>
          <pub-id pub-id-type="pmid">9217007</pub-id>
        </citation>
      </ref>
      <ref id="B6">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kaartinen</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Voncken</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>Shuler</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Warburton</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Bu</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Heisterkamp</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Groffen</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Abnormal lung development and cleft palate in mice lacking TGF-Î²3 indicates defects of epithelial-mesenchymal interaction</article-title>
          <source>Nat Genet</source>
          <year>1995</year>
          <volume>11</volume>
          <fpage>415</fpage>
          <lpage>421</lpage>
          <pub-id pub-id-type="pmid">7493022</pub-id>
          <pub-id pub-id-type="doi">10.1038/ng1295-415</pub-id>
        </citation>
      </ref>
      <ref id="B7">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Proetzel</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Pawlowski</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Wiles</surname>
              <given-names>MV</given-names>
            </name>
            <name>
              <surname>Yin</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Boivin</surname>
              <given-names>GP</given-names>
            </name>
            <name>
              <surname>Howles</surname>
              <given-names>PN</given-names>
            </name>
            <name>
              <surname>Ding</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Ferguson</surname>
              <given-names>MW</given-names>
            </name>
            <name>
              <surname>Doetschman</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Transforming growth factor-Î²3 is required for secondary palate fusion</article-title>
          <source>Nat Genet</source>
          <year>1995</year>
          <volume>11</volume>
          <fpage>409</fpage>
          <lpage>414</lpage>
          <pub-id pub-id-type="pmid">7493021</pub-id>
          <pub-id pub-id-type="doi">10.1038/ng1295-409</pub-id>
        </citation>
      </ref>
      <ref id="B8">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Koli</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Saharinen</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Hyytiainen</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Penttinen</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Keski-Oja</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Latency, activation, and binding proteins of TGF-beta</article-title>
          <source>Microsc Res Tech</source>
          <year>2001</year>
          <volume>52</volume>
          <fpage>354</fpage>
          <lpage>362</lpage>
          <pub-id pub-id-type="pmid">11170294</pub-id>
          <pub-id pub-id-type="doi">10.1002/1097-0029(20010215)52:4&lt;354::AID-JEMT1020&gt;3.0.CO;2-G</pub-id>
        </citation>
      </ref>
      <ref id="B9">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lutz</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Knaus</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Integration of the TGF-beta pathway into the cellular signalling network</article-title>
          <source>Cell Signal</source>
          <year>2002</year>
          <volume>14</volume>
          <fpage>977</fpage>
          <lpage>988</lpage>
          <pub-id pub-id-type="pmid">12359303</pub-id>
          <pub-id pub-id-type="doi">10.1016/S0898-6568(02)00058-X</pub-id>
        </citation>
      </ref>
      <ref id="B10">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rotzer</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Roth</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Lutz</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Lindemann</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Sebald</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Knaus</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Type III TGF-Î² receptor-independent signalling of TGF-Î²2 via TÎ²RII-B, an alternatively spliced TGF-Î² type II receptor</article-title>
          <source>EMBO J</source>
          <year>2001</year>
          <volume>20</volume>
          <fpage>480</fpage>
          <lpage>490</lpage>
          <pub-id pub-id-type="pmid">11157754</pub-id>
          <pub-id pub-id-type="doi">10.1093/emboj/20.3.480</pub-id>
        </citation>
      </ref>
      <ref id="B11">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Parker</surname>
              <given-names>WL</given-names>
            </name>
            <name>
              <surname>Finnson</surname>
              <given-names>KW</given-names>
            </name>
            <name>
              <surname>Soe-Lin</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Knaus</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Philip</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Expression and function of TÎ²RII-B, a variant of the type II TGF-Î² receptor, in human chondrocytes</article-title>
          <source>Osteoarthritis Cartilage</source>
          <year>2007</year>
          <volume>15</volume>
          <fpage>442</fpage>
          <lpage>453</lpage>
          <pub-id pub-id-type="pmid">17175180</pub-id>
          <pub-id pub-id-type="doi">10.1016/j.joca.2006.10.006</pub-id>
        </citation>
      </ref>
      <ref id="B12">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ikeda</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Lioubin</surname>
              <given-names>MN</given-names>
            </name>
            <name>
              <surname>Marquardt</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Human transforming growth factor type Î²2: production by a prostatic adenocarcinoma cell line, purification, and initial characterization</article-title>
          <source>Biochemistry</source>
          <year>1987</year>
          <volume>26</volume>
          <fpage>2406</fpage>
          <lpage>2410</lpage>
          <pub-id pub-id-type="pmid">3475130</pub-id>
          <pub-id pub-id-type="doi">10.1021/bi00383a002</pub-id>
        </citation>
      </ref>
      <ref id="B13">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tomoda</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Kudoh</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Noma</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Nakazawa</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Muramatsu</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Arai</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Molecular cloning of a mouse counterpart for human TGF-beta type I receptor</article-title>
          <source>Biochem Biophys Res Commun</source>
          <year>1994</year>
          <volume>198</volume>
          <fpage>1054</fpage>
          <lpage>1062</lpage>
          <pub-id pub-id-type="pmid">8117261</pub-id>
          <pub-id pub-id-type="doi">10.1006/bbrc.1994.1150</pub-id>
        </citation>
      </ref>
      <ref id="B14">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Danielpour</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Functions and regulation of transforming growth factor-beta (TGF-Î²) in the prostate</article-title>
          <source>Eur J Cancer</source>
          <year>2005</year>
          <volume>41</volume>
          <fpage>846</fpage>
          <lpage>857</lpage>
          <pub-id pub-id-type="pmid">15808954</pub-id>
          <pub-id pub-id-type="doi">10.1016/j.ejca.2004.12.027</pub-id>
        </citation>
      </ref>
      <ref id="B15">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shariat</surname>
              <given-names>SF</given-names>
            </name>
            <name>
              <surname>Shalev</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Menesses-Diaz</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>IY</given-names>
            </name>
            <name>
              <surname>Kattan</surname>
              <given-names>MW</given-names>
            </name>
            <name>
              <surname>Wheeler</surname>
              <given-names>TM</given-names>
            </name>
            <name>
              <surname>Slawin</surname>
              <given-names>KM</given-names>
            </name>
          </person-group>
          <article-title>Preoperative plasma levels of transforming growth factor beta1 (TGF-Î²1) strongly predict progression in patients undergoing radical prostatectomy</article-title>
          <source>J Clin Oncol</source>
          <year>2001</year>
          <volume>19</volume>
          <fpage>2856</fpage>
          <lpage>2864</lpage>
          <pub-id pub-id-type="pmid">11387358</pub-id>
        </citation>
      </ref>
      <ref id="B16">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shariat</surname>
              <given-names>SF</given-names>
            </name>
            <name>
              <surname>Menesses-Diaz</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>IY</given-names>
            </name>
            <name>
              <surname>Muramoto</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Wheeler</surname>
              <given-names>TM</given-names>
            </name>
            <name>
              <surname>Slawin</surname>
              <given-names>KM</given-names>
            </name>
          </person-group>
          <article-title>Tissue expression of transforming growth factor-Î²1 and its receptors: correlation with pathologic features and biochemical progression in patients undergoing radical prostatectomy</article-title>
          <source>Urology</source>
          <year>2004</year>
          <volume>63</volume>
          <fpage>1191</fpage>
          <lpage>1197</lpage>
          <pub-id pub-id-type="pmid">15183988</pub-id>
          <pub-id pub-id-type="doi">10.1016/j.urology.2003.12.015</pub-id>
        </citation>
      </ref>
      <ref id="B17">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Modrek</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>A genomic view of alternative splicing</article-title>
          <source>Nat Genet</source>
          <year>2002</year>
          <volume>30</volume>
          <fpage>13</fpage>
          <lpage>19</lpage>
          <pub-id pub-id-type="pmid">11753382</pub-id>
          <pub-id pub-id-type="doi">10.1038/ng0102-13</pub-id>
        </citation>
      </ref>
      <ref id="B18">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Black</surname>
              <given-names>DL</given-names>
            </name>
          </person-group>
          <article-title>Protein diversity from alternative splicing: a challenge for bioinformatics and post-genome biology</article-title>
          <source>Cell</source>
          <year>2000</year>
          <volume>103</volume>
          <fpage>367</fpage>
          <lpage>370</lpage>
          <pub-id pub-id-type="pmid">11081623</pub-id>
          <pub-id pub-id-type="doi">10.1016/S0092-8674(00)00128-8</pub-id>
        </citation>
      </ref>
      <ref id="B19">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Caceres</surname>
              <given-names>JF</given-names>
            </name>
            <name>
              <surname>Kornblihtt</surname>
              <given-names>AR</given-names>
            </name>
          </person-group>
          <article-title>Alternative splicing: multiple control mechanisms and involvement in human disease</article-title>
          <source>Trends Genet</source>
          <year>2002</year>
          <volume>18</volume>
          <fpage>186</fpage>
          <lpage>193</lpage>
          <pub-id pub-id-type="pmid">11932019</pub-id>
          <pub-id pub-id-type="doi">10.1016/S0168-9525(01)02626-9</pub-id>
        </citation>
      </ref>
      <ref id="B20">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hu</surname>
              <given-names>GK</given-names>
            </name>
            <name>
              <surname>Madore</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Moldover</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Jatkoe</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Balaban</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Thomas</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>Predicting splice variant from DNA chip expression data</article-title>
          <source>Genome Res</source>
          <year>2001</year>
          <volume>11</volume>
          <fpage>1237</fpage>
          <lpage>1245</lpage>
          <pub-id pub-id-type="pmid">11435406</pub-id>
          <pub-id pub-id-type="doi">10.1101/gr.165501</pub-id>
        </citation>
      </ref>
      <ref id="B21">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dralyuk</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Brudno</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Gelfand</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Zorn</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Dubchak</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
          <article-title>ASDB: database of alternatively spliced genes</article-title>
          <source>Nucleic Acids Res</source>
          <year>2000</year>
          <volume>28</volume>
          <fpage>296</fpage>
          <lpage>297</lpage>
          <pub-id pub-id-type="pmid">10592252</pub-id>
          <pub-id pub-id-type="doi">10.1093/nar/28.1.296</pub-id>
        </citation>
      </ref>
      <ref id="B22">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brett</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Pospisil</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Valcarcel</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Reich</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Bork</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Alternative splicing and genome complexity</article-title>
          <source>Nat Genet</source>
          <year>2002</year>
          <volume>30</volume>
          <fpage>29</fpage>
          <lpage>30</lpage>
          <pub-id pub-id-type="pmid">11743582</pub-id>
          <pub-id pub-id-type="doi">10.1038/ng803</pub-id>
        </citation>
      </ref>
      <ref id="B23">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Modrek</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>CJ</given-names>
            </name>
          </person-group>
          <article-title>Alternative splicing in the human, mouse and rat genomes is associated with an increased frequency of exon creation and/or loss</article-title>
          <source>Nat Genet</source>
          <year>2003</year>
          <volume>34</volume>
          <fpage>177</fpage>
          <lpage>180</lpage>
          <pub-id pub-id-type="pmid">12730695</pub-id>
          <pub-id pub-id-type="doi">10.1038/ng1159</pub-id>
        </citation>
      </ref>
      <ref id="B24">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kondaiah</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Van Obberghen-Schilling</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Ludwig</surname>
              <given-names>RL</given-names>
            </name>
            <name>
              <surname>Dhar</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Sporn</surname>
              <given-names>MB</given-names>
            </name>
            <name>
              <surname>Roberts</surname>
              <given-names>AB</given-names>
            </name>
          </person-group>
          <article-title>cDNA cloning of porcine transforming growth factor-Î²1 mRNAs. Evidence for alternate splicing and polyadenylation</article-title>
          <source>J Biol Chem</source>
          <year>1988</year>
          <volume>263</volume>
          <fpage>18313</fpage>
          <lpage>18317</lpage>
          <pub-id pub-id-type="pmid">2461367</pub-id>
        </citation>
      </ref>
      <ref id="B25">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Koishi</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Dalzell</surname>
              <given-names>KG</given-names>
            </name>
            <name>
              <surname>McLennan</surname>
              <given-names>IS</given-names>
            </name>
          </person-group>
          <article-title>The expression and structure of TGF-Î²2 transcripts in rat muscles</article-title>
          <source>Biochim Biophys Acta</source>
          <year>2000</year>
          <volume>1492</volume>
          <fpage>311</fpage>
          <lpage>319</lpage>
          <pub-id pub-id-type="pmid">10899565</pub-id>
        </citation>
      </ref>
      <ref id="B26">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Agrotis</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Condron</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Bobik</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Alternative splicing within the TGF-Î²I receptor gene (ALK-5) generates two major functional isoforms in vascular smooth muscle cells</article-title>
          <source>FEBS Lett</source>
          <year>2002</year>
          <volume>467</volume>
          <fpage>128</fpage>
          <lpage>132</lpage>
          <pub-id pub-id-type="pmid">10664470</pub-id>
          <pub-id pub-id-type="doi">10.1016/S0014-5793(00)01132-7</pub-id>
        </citation>
      </ref>
      <ref id="B27">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chen</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Rund</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>Beever</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Schook</surname>
              <given-names>LB</given-names>
            </name>
          </person-group>
          <article-title>Isolation and molecular characterization of the porcine transforming growth factor beta type I receptor (TGFBR1) gene</article-title>
          <source>Gene</source>
          <year>2006</year>
          <volume>384</volume>
          <fpage>62</fpage>
          <lpage>72</lpage>
          <pub-id pub-id-type="pmid">16950575</pub-id>
          <pub-id pub-id-type="doi">10.1016/j.gene.2006.07.009</pub-id>
        </citation>
      </ref>
      <ref id="B28">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Suzuki</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Shioda</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Maeda</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Tada</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ueno</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
          <article-title>Cloning of an isoform of mouse TGF-beta type II receptor gene</article-title>
          <source>FEBS Lett</source>
          <year>1994</year>
          <volume>355</volume>
          <fpage>19</fpage>
          <lpage>22</lpage>
          <pub-id pub-id-type="pmid">7957954</pub-id>
          <pub-id pub-id-type="doi">10.1016/0014-5793(94)01156-7</pub-id>
        </citation>
      </ref>
      <ref id="B29">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hirai</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Fujita</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>A human transforming growth factor-Î² type II receptor that contains an insertion in the extracellular domain</article-title>
          <source>Exp Cell Res</source>
          <year>1996</year>
          <volume>223</volume>
          <fpage>135</fpage>
          <lpage>141</lpage>
          <pub-id pub-id-type="pmid">8635485</pub-id>
          <pub-id pub-id-type="doi">10.1006/excr.1996.0066</pub-id>
        </citation>
      </ref>
      <ref id="B30">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ogasa</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Noma</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Murata</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Kawai</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Nakazawa</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Cloning of a cDNA encoding the human transforming growth factor-beta type II receptor: heterogeneity of the mRNA</article-title>
          <source>Gene</source>
          <year>1996</year>
          <volume>181</volume>
          <fpage>185</fpage>
          <lpage>190</lpage>
          <pub-id pub-id-type="pmid">8973329</pub-id>
          <pub-id pub-id-type="doi">10.1016/S0378-1119(96)00501-X</pub-id>
        </citation>
      </ref>
      <ref id="B31">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lee</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Atanelov</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Modrek</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Xing</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>ASAP: the Alternative Splicing Annotation Project</article-title>
          <source>Nucleic Acids Res</source>
          <year>2003</year>
          <volume>31</volume>
          <fpage>101</fpage>
          <lpage>105</lpage>
          <pub-id pub-id-type="pmid">12519958</pub-id>
          <pub-id pub-id-type="doi">10.1093/nar/gkg029</pub-id>
        </citation>
      </ref>
      <ref id="B32">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pospisil</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Herrmann</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Bortfeldt</surname>
              <given-names>RH</given-names>
            </name>
            <name>
              <surname>Reich</surname>
              <given-names>JG</given-names>
            </name>
          </person-group>
          <article-title>EASED: Extended Alternatively Spliced EST Database</article-title>
          <source>Nucleic Acids Res</source>
          <year>2004</year>
          <fpage>D70</fpage>
          <lpage>74</lpage>
          <pub-id pub-id-type="pmid">14681361</pub-id>
          <pub-id pub-id-type="doi">10.1093/nar/gkh136</pub-id>
        </citation>
      </ref>
      <ref id="B33">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Janssen</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Albrecht</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Moschler</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Renneberg</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Fritz</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Aumuller</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Konrad</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Cell lineage characteristics of human prostatic stromal cells cultured in vitro</article-title>
          <source>Prostate</source>
          <year>2000</year>
          <volume>43</volume>
          <fpage>20</fpage>
          <lpage>30</lpage>
          <pub-id pub-id-type="pmid">10725862</pub-id>
          <pub-id pub-id-type="doi">10.1002/(SICI)1097-0045(20000401)43:1&lt;20::AID-PROS4&gt;3.0.CO;2-6</pub-id>
        </citation>
      </ref>
      <ref id="B34">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kochiwa</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Suzuki</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Washio</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Saito</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Bono</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Carninci</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Okazaki</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Miki</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Hayashizaki</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Tomita</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>RIKEN Genome Exploration Research Group Phase II Team, Inferring alternative splicing patterns in mouse from a full-length cDNA library and microarray data</article-title>
          <source>Genome Res</source>
          <year>2002</year>
          <volume>12</volume>
          <fpage>1286</fpage>
          <lpage>1293</lpage>
          <pub-id pub-id-type="pmid">12176936</pub-id>
          <pub-id pub-id-type="doi">10.1101/gr.220302</pub-id>
        </citation>
      </ref>
      <ref id="B35">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yang</surname>
              <given-names>HK</given-names>
            </name>
            <name>
              <surname>Kang</surname>
              <given-names>SH</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>YS</given-names>
            </name>
            <name>
              <surname>Won</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Bang</surname>
              <given-names>YJ</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>SJ</given-names>
            </name>
          </person-group>
          <article-title>Truncation of the TGF-beta type II receptor gene results in insensitivity to TGF-beta in human gastric cancer cells</article-title>
          <source>Oncogene</source>
          <year>1999</year>
          <volume>18</volume>
          <fpage>2213</fpage>
          <lpage>2219</lpage>
          <pub-id pub-id-type="pmid">10327067</pub-id>
          <pub-id pub-id-type="doi">10.1038/sj.onc.1202535</pub-id>
        </citation>
      </ref>
      <ref id="B36">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lyon</surname>
              <given-names>PB</given-names>
            </name>
            <name>
              <surname>See</surname>
              <given-names>WA</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Cohen</surname>
              <given-names>MB</given-names>
            </name>
          </person-group>
          <article-title>Diversity and modulation of plasminogen activator activity in human prostate carcinoma cell lines</article-title>
          <source>Prostate</source>
          <year>1995</year>
          <volume>27</volume>
          <fpage>179</fpage>
          <lpage>186</lpage>
          <pub-id pub-id-type="pmid">7479384</pub-id>
          <pub-id pub-id-type="doi">10.1002/pros.2990270402</pub-id>
        </citation>
      </ref>
      <ref id="B37">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dahiya</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Haughney</surname>
              <given-names>PC</given-names>
            </name>
            <name>
              <surname>Chui</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Ho</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Deng</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Differential gene expression of transforming growth factors alpha and beta, epidermal growth factor, keratinocyte growth factor, and their receptors in fetal and adult human prostatic tissues and cancer cell lines</article-title>
          <source>Urology</source>
          <year>1996</year>
          <volume>48</volume>
          <fpage>963</fpage>
          <lpage>970</lpage>
          <pub-id pub-id-type="pmid">8973690</pub-id>
          <pub-id pub-id-type="doi">10.1016/S0090-4295(96)00376-7</pub-id>
        </citation>
      </ref>
      <ref id="B38">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jones</surname>
              <given-names>HE</given-names>
            </name>
            <name>
              <surname>Eaton</surname>
              <given-names>CL</given-names>
            </name>
            <name>
              <surname>Barrow</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Dutkowski</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Gee</surname>
              <given-names>JMW</given-names>
            </name>
            <name>
              <surname>Griffiths</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Comparative studies of the mitogenic effects of epidermal growth factor and transforming growth factor-Î± and the expression of various growth factors in neoplastic and non-neoplastic prostatic cell lines</article-title>
          <source>Prostate</source>
          <year>1997</year>
          <volume>30</volume>
          <fpage>219</fpage>
          <lpage>231</lpage>
          <pub-id pub-id-type="pmid">9111599</pub-id>
          <pub-id pub-id-type="doi">10.1002/(SICI)1097-0045(19970301)30:4&lt;219::AID-PROS1&gt;3.0.CO;2-G</pub-id>
        </citation>
      </ref>
      <ref id="B39">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wilding</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Zugmeier</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Knabbe</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Flanders</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Gelmann</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Differential effects of transforming growth factor Î² on human prostate cancer cells in vitro</article-title>
          <source>Mol Cell Endocrinol</source>
          <year>1989</year>
          <volume>62</volume>
          <fpage>79</fpage>
          <lpage>87</lpage>
          <pub-id pub-id-type="pmid">2545487</pub-id>
          <pub-id pub-id-type="doi">10.1016/0303-7207(89)90115-9</pub-id>
        </citation>
      </ref>
      <ref id="B40">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Blanchere</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Saunier</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Mestayer</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Broshuis</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Mowszowicz</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
          <article-title>Alterations of expression and regulation of transforming growth factor Î² in human cancer prostate cell lines</article-title>
          <source>J Steroid Biochem Mol Biol</source>
          <year>2002</year>
          <volume>82</volume>
          <fpage>297</fpage>
          <lpage>304</lpage>
          <pub-id pub-id-type="pmid">12589936</pub-id>
          <pub-id pub-id-type="doi">10.1016/S0960-0760(02)00218-2</pub-id>
        </citation>
      </ref>
      <ref id="B41">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Klingler</surname>
              <given-names>HC</given-names>
            </name>
            <name>
              <surname>Bretland</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Reid</surname>
              <given-names>SV</given-names>
            </name>
            <name>
              <surname>Chapple</surname>
              <given-names>CR</given-names>
            </name>
            <name>
              <surname>Eaton</surname>
              <given-names>CL</given-names>
            </name>
          </person-group>
          <article-title>Regulation of prostatic stromal cell growth and function by transforming growth factor beta (TGFbeta)</article-title>
          <source>Prostate</source>
          <year>1999</year>
          <volume>41</volume>
          <fpage>110</fpage>
          <lpage>120</lpage>
          <pub-id pub-id-type="pmid">10477907</pub-id>
          <pub-id pub-id-type="doi">10.1002/(SICI)1097-0045(19991001)41:2&lt;110::AID-PROS5&gt;3.0.CO;2-X</pub-id>
        </citation>
      </ref>
      <ref id="B42">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kim</surname>
              <given-names>IY</given-names>
            </name>
            <name>
              <surname>Ahn</surname>
              <given-names>HJ</given-names>
            </name>
            <name>
              <surname>Zelner</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Shaw</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>Sensibar</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Kato</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Genetic change in transforming growth factor-Î² (TGF-Î²) receptor type I gene correlates with insensitivity to TGF-Î²1 in human prostate cancer cells</article-title>
          <source>Cancer Res</source>
          <year>1996</year>
          <volume>56</volume>
          <fpage>44</fpage>
          <lpage>48</lpage>
          <pub-id pub-id-type="pmid">8548772</pub-id>
        </citation>
      </ref>
      <ref id="B43">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kim</surname>
              <given-names>IY</given-names>
            </name>
            <name>
              <surname>Zehner</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>The conventional transforming growth factor-Î² (TGF-Î²) receptor type I is not required for TGF-Î²1 signaling in a human prostate cancer cell line, LNCaP</article-title>
          <source>Exp Cell Res</source>
          <year>1998</year>
          <volume>241</volume>
          <fpage>151</fpage>
          <lpage>160</lpage>
          <pub-id pub-id-type="pmid">9633523</pub-id>
          <pub-id pub-id-type="doi">10.1006/excr.1998.4034</pub-id>
        </citation>
      </ref>
      <ref id="B44">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jakowlew</surname>
              <given-names>SB</given-names>
            </name>
            <name>
              <surname>Moody</surname>
              <given-names>TW</given-names>
            </name>
            <name>
              <surname>Mariano</surname>
              <given-names>JM</given-names>
            </name>
          </person-group>
          <article-title>Transforming growth factor-beta receptors in human cancer cell lines: analysis of transcript, protein and proliferation</article-title>
          <source>Anticancer Res</source>
          <year>1997</year>
          <volume>17</volume>
          <fpage>1849</fpage>
          <lpage>1860</lpage>
          <pub-id pub-id-type="pmid">9216635</pub-id>
        </citation>
      </ref>
      <ref id="B45">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Butter</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Laping</surname>
              <given-names>NJ</given-names>
            </name>
            <name>
              <surname>Pullen</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Grygielko</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Olson</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Brooks</surname>
              <given-names>DP</given-names>
            </name>
          </person-group>
          <article-title>The role of transforming growth factor-Î² and its receptors in human prostate smooth muscle cell fibronectin production</article-title>
          <source>Eur J Pharmacol</source>
          <year>2001</year>
          <volume>422</volume>
          <fpage>47</fpage>
          <lpage>52</lpage>
          <pub-id pub-id-type="pmid">11430912</pub-id>
          <pub-id pub-id-type="doi">10.1016/S0014-2999(01)01072-X</pub-id>
        </citation>
      </ref>
      <ref id="B46">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Del Re</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Babitt</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Pirani</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Schneyer</surname>
              <given-names>AL</given-names>
            </name>
            <name>
              <surname>Lin</surname>
              <given-names>HY</given-names>
            </name>
          </person-group>
          <article-title>In the absence of type III receptor, the TGF-Î² type II-B receptor requires the type I receptor to bind TGF-Î²2</article-title>
          <source>J Biol Chem</source>
          <year>2004</year>
          <volume>279</volume>
          <fpage>22765</fpage>
          <lpage>22772</lpage>
          <pub-id pub-id-type="pmid">14996829</pub-id>
          <pub-id pub-id-type="doi">10.1074/jbc.M401350200</pub-id>
        </citation>
      </ref>
      <ref id="B47">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Larsson</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Goumans</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Sjostrand</surname>
              <given-names>LJ</given-names>
            </name>
            <name>
              <surname>van Rooijen</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Ward</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Leveen</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>ten Dijke</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Mummery</surname>
              <given-names>CL</given-names>
            </name>
            <name>
              <surname>Karlsson</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Abnormal angiogenesis but intact hematopoietic potential in TGF-Î² type I receptor-deficient mice</article-title>
          <source>EMBO J</source>
          <year>2001</year>
          <volume>20</volume>
          <fpage>1663</fpage>
          <lpage>1673</lpage>
          <pub-id pub-id-type="pmid">11285230</pub-id>
          <pub-id pub-id-type="doi">10.1093/emboj/20.7.1663</pub-id>
        </citation>
      </ref>
      <ref id="B48">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Oshima</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Oshima</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Taketo</surname>
              <given-names>MM</given-names>
            </name>
          </person-group>
          <article-title>TGF-Î² receptor type II deficiency results in defects of yolk sac hematopoiesis and vasculogenesis</article-title>
          <source>Dev Biol</source>
          <year>1996</year>
          <volume>179</volume>
          <fpage>297</fpage>
          <lpage>302</lpage>
          <pub-id pub-id-type="pmid">8873772</pub-id>
          <pub-id pub-id-type="doi">10.1006/dbio.1996.0259</pub-id>
        </citation>
      </ref>
      <ref id="B49">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stenvers</surname>
              <given-names>KL</given-names>
            </name>
            <name>
              <surname>Tursky</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Harder</surname>
              <given-names>KW</given-names>
            </name>
            <name>
              <surname>Kountouri</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Amatayakul-Chantler</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Grail</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Small</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Weinberg</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Sizeland</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Zhu</surname>
              <given-names>HJ</given-names>
            </name>
          </person-group>
          <article-title>Heart and liver defects and reduced transforming growth factor Î²2 sensitivity in transforming growth factor Î² type III receptor-deficient embryos</article-title>
          <source>Mol Cell Biol</source>
          <year>2003</year>
          <volume>23</volume>
          <fpage>4371</fpage>
          <lpage>4385</lpage>
          <pub-id pub-id-type="pmid">12773577</pub-id>
          <pub-id pub-id-type="doi">10.1128/MCB.23.12.4371-4385.2003</pub-id>
        </citation>
      </ref>
      <ref id="B50">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Webb</surname>
              <given-names>NR</given-names>
            </name>
            <name>
              <surname>Madisen</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Rose</surname>
              <given-names>TM</given-names>
            </name>
            <name>
              <surname>Purchio</surname>
              <given-names>AF</given-names>
            </name>
          </person-group>
          <article-title>Structural and sequence analysis of TGF-Î²2 cDNA clones predicts two different precursor proteins produced by alternative mRNA splicing</article-title>
          <source>DNA</source>
          <year>1988</year>
          <volume>7</volume>
          <fpage>493</fpage>
          <lpage>497</lpage>
          <pub-id pub-id-type="pmid">2850146</pub-id>
        </citation>
      </ref>
      <ref id="B51">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Konrad</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Luers</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Volck-Badouin</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Keilani</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Laible</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>AumÃ¼ller</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Hofmann</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Analysis of the mRNA expression of the TGF-beta family in testicular cells and localization of the splice variant TGF-Î²2B in testis</article-title>
          <source>Mol Reprod Dev</source>
          <year>2006</year>
          <volume>73</volume>
          <fpage>1211</fpage>
          <lpage>1220</lpage>
          <pub-id pub-id-type="pmid">16868931</pub-id>
          <pub-id pub-id-type="doi">10.1002/mrd.20399</pub-id>
        </citation>
      </ref>
      <ref id="B52">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Madisen</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Lioubin</surname>
              <given-names>MN</given-names>
            </name>
            <name>
              <surname>Finerty</surname>
              <given-names>PJ</given-names>
              <suffix>Jr</suffix>
            </name>
            <name>
              <surname>Sutter</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Blake</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Frederick</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Purchio</surname>
              <given-names>AF</given-names>
            </name>
          </person-group>
          <article-title>Expression of recombinant TGF-beta 2(442) precursor and detection in BSC-40 cells</article-title>
          <source>Growth Factors</source>
          <year>1991</year>
          <volume>5</volume>
          <fpage>317</fpage>
          <lpage>325</lpage>
          <pub-id pub-id-type="pmid">1777240</pub-id>
        </citation>
      </ref>
      <ref id="B53">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Renneberg</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Friedetzky</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Konrad</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Kurek</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Weingartner</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Wennemuth</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Tunn</surname>
              <given-names>UW</given-names>
            </name>
            <name>
              <surname>Aumuller</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Prostate specific membrane antigen (PSM) is expressed in various human tissues: implication for the use of PSM reverse transcription polymerase chain reaction to detect hematogenous prostate cancer spread</article-title>
          <source>Urol Res</source>
          <year>1999</year>
          <volume>27</volume>
          <fpage>23</fpage>
          <lpage>27</lpage>
          <pub-id pub-id-type="pmid">10092150</pub-id>
          <pub-id pub-id-type="doi">10.1007/s002400050085</pub-id>
        </citation>
      </ref>
      <ref id="B54">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Frohman</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Dush</surname>
              <given-names>MK</given-names>
            </name>
            <name>
              <surname>Martin</surname>
              <given-names>GR</given-names>
            </name>
          </person-group>
          <article-title>Rapid production of full-length cDNAs from rare transcripts: amplification using a single gene-specific oligonucleotide primer</article-title>
          <source>Proc Natl Acad Sci USA</source>
          <year>1988</year>
          <volume>85</volume>
          <fpage>8998</fpage>
          <lpage>9002</lpage>
          <pub-id pub-id-type="pmid">2461560</pub-id>
          <pub-id pub-id-type="doi">10.1073/pnas.85.23.8998</pub-id>
        </citation>
      </ref>
      <ref id="B55">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Albrecht</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Renneberg</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Wennemuth</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Moschler</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Janssen</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Aumuller</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Konrad</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Fibronectin in human prostatic cells in vivo and in vitro: expression, distribution, and pathological significance</article-title>
          <source>Histochem Cell Biol</source>
          <year>1999</year>
          <volume>112</volume>
          <fpage>51</fpage>
          <lpage>61</lpage>
          <pub-id pub-id-type="pmid">10461812</pub-id>
          <pub-id pub-id-type="doi">10.1007/s004180050391</pub-id>
        </citation>
      </ref>
      <ref id="B56">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>von Knobloch</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Hegele</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Brandt</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Varga</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Wille</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kalble</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Heidenreich</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Hofmann</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>High frequency of serum DNA alterations in renal cell carcinoma detected by fluorescent microsatellite analysis</article-title>
          <source>Int J Cancer</source>
          <year>2002</year>
          <volume>98</volume>
          <fpage>889</fpage>
          <lpage>894</lpage>
          <pub-id pub-id-type="pmid">11948468</pub-id>
          <pub-id pub-id-type="doi">10.1002/ijc.10263</pub-id>
        </citation>
      </ref>
    </ref-list>
  </back>
</article>

</metadata></record></GetRecord></OAI-PMH>